{"title": "B\u00fasqueda", "author": null, "url": "https://www.saludyfarmacos.org/lang/es/boletin-farmacos/boletines/jun2001/indice", "hostname": "saludyfarmacos.org", "description": null, "sitename": "saludyfarmacos.org", "date": "1995-01-01", "id": null, "license": "CC BY-NC-SA 4.0", "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "|\n|[El role del farmac\u00e9utico comunitario en la identificaci\u00f3n, prevenci\u00f3n y resoluci\u00f3n de problemas relacionados con medicamentos (The role of the community pharmacist in identifying, preventing, and resolving drug-related problems ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9b08)\nCerulli JMedscape Pharmacist 30 de julio de 2001\n|\n|[\u00bfEs posible disminuir la prescripci\u00f3n de antibi\u00f3ticos en atenci\u00f3n primaria? Un an\u00e1lisis de los resultados del manejo de pacientes con afecciones de garganta (Is it posible to decrease antibiotic prescribing in primary care? An analysis of outcomes in the management of patients with sore throats). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista30f6)\nCox Cl M y Jones M.\nFamily Practice 2001; 18: 9-13\n|\n|\nEnfermedades meningoc\u00f3cicas: nuevas estrategias de prenvenci\u00f3n\nSoult Rubio JA, Mu\u00f1oz M y L\u00f3pez Castilla JD\nAnales Espa\u00f1oles de Pediatr\u00eda 2001; 54 (1): 65-68.\n|\n|\nPuesta al d\u00eda de enfermedades infecciosas pedi\u00e1tricas: Erradicaci\u00f3n de la polio, y el diagn\u00f3stico y tratamiento de la infecci\u00f3n estreptoc\u00f3cica (Pediatric ID update: polio eradication, and diagnosing and treating strep infections)\nSteele RW\nMedscape Infectious Disease 2001; 3(3)\n|\n|\nUso del zanamivir para el tratamiento de la infecci\u00f3n por influenza A y B en pacientes de alto riesgo. An\u00e1lisis de ensayos cl\u00ednicos aleatorios (Zanamivir for the treatment of influenza A and B infection in high-risk patients: A pooled analysis of randomized controlled trials)\nLalezari J, Campion K, Keene O, y Silagy Ch.\nArchives of Internal Medicine, 2001; 161(2):212-17\n|\n|\nCapacitaci\u00f3n de maestros y grupos de mujeres para mejorar el uso de medicamentos en la comunidad (Training intervention to improve the use of medicines in the community through school teachers and women groups)\nKafle KK, Humagian BR, tapa BB, Shrestha BM, Bhuju GB, DC GB, Prasad RR y Rajbhandari V\nPharmaceutical Horizon of Nepal,\n[phon1993@hotmail.com](mailto:phon1993@hotmail.com)\n|\n|\nPrevenci\u00f3n de la transmisi\u00f3n de la VIH durante el embarazo (Preventing HIV transmission during pregnancy)\nShah SS y McGowan JP\nInfect. Med. 2001; 18 (2): 94-105\n|\n|\nUso del misoprostol por v\u00eda rectal en aton\u00eda uterina que no responden al tratamiento convencional\nSandoval J, Guti\u00e9rrez M, D\u00edaz N y Paz P.\nGinecolog\u00eda y Obstetricia (Per\u00fa) 2000; 46 (3): 1\n|\n|\nMexazolam y alprazolam en el tratamiento de la ansiedad generalizada: un ensayo cl\u00ednico a doble ciego (Mexazolam and alprazolam in the treatment of genralised anxiety disorder: a double-blind, randomized clinical trial)\nVaz Serra A, Figueira ML, Bessa-Peixoto A, Firmino H, Albuquerque R, Paz C, Vaz-Silva M, y Almeida L\nClinical Drug Investigation 1001; 21(4): 257-263\n|\n|\nTratamiento de la enfermedad pulmonar obstructiva cr\u00f3nica \u00fanicamente con formoterol o con la combinaci\u00f3n de bromuro de ipratropiomo y de fenoterol (Formoterol monotherapy compared uit combined ipratropium bromide plus fenoterol in the treatment of chronic obstructive pulmonary disease)\nKonerman M, Suchantke R, Mogck J, Brauburger J y Brautigam M.\nClinical Drug Investigation 2001; 21(4):235-242.\n|\n|\nUso de las estatinas en pacientes despu\u00e9s de un infarto del miocardio agudo: \u00bfLa evidencia hace que se cambie la pr\u00e1ctica? (Use of statins in patients after acute myocardial infarction: does evidence change practice?)\nJackevicius CA, Anderson G, Leiter L y Tu J.\nArchives of Internal Medicine 2001;161: 183-188.\n|\n|\nTerapias antihipertensivas y riesgo de accidente vascular cerebral isqu\u00e9mico (Antihypertensive drug therapies and the risk of ischaemic stroke)\nKlungel OH, Heckbert SR, Longtreth WT, Furberg CD, Caplan RC, Smith NL, Lemaitre RN, Leufkens HGM, de Boer A y Psaty BM.\nArchives of Internal Medicine 2001; 161:37-43\n|\n|\nEl uso cl\u00ednico de las nuevas terapias antitromb\u00f3ticas en el manejo de s\u00edndromes coronarios agudos (Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes)\nWigginns BS, Wittkowsky AK, y Nappi JM\nPharmacotherapy 2001; 21(3): 320-337\n|\n|\nPrescripci\u00f3n, acceso y gasto en medicamentos entre usuarios de servicios de salud en M\u00e9xico\nReyna-Flores R, Erviti-Erice J, Kageyama-Escobar ML y Arredondo A\nSalud P\u00fablica de M\u00e9xico 1998; 40(1): 24-31\n|\n|\nDesempe\u00f1o de un programa computarizado para detectar interacciones medicamentosas en las farmacias comunitarias (Performance of community pharmacy drug interaction software)\nHazlet TK, Lee TA, Hansen PD y Horn JR\nJournal of the American Pharmaceutical Association 2001;41 (2): 200-204\n|\n|\nEvaluaci\u00f3n de los estudios que investigan la efectividad de los servicios cl\u00ednicos ofrecidos por farmac\u00e9uticos (Evaluation of studies investigating the effectiveness of pharmacists\u2019 clinical services)\nMorrison A y Wertheimer AI\nAmerican Journal of Health Systems Pharmacy 2001; 58 (7): 569-577\n|\n|\nErrores en la medicaci\u00f3n: el impacto de la asociaci\u00f3n de farmacia (Medication errors: the pharmacy association\u2019s impact)\nFeinberg DB\nMedscape Pharmacists 2001: 2(2)\n[http://www.medscape.com/Medscape/pharmacists/journal/2001/v02.n02](http://www.medscape.com/Medscape/pharmacists/journal/2001/v02.n02)\n|\n|[El papel de la farmacoeconom\u00eda desde el punto de vista de la industria farmac\u00e9utica (The role of pharmacoeconomic information from the pharmaceutical industry perpective) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4cad)Armstrong EP, Abarca J, y Grizzle AJ.Drug Benefit Trends 2001;13(3): 39-45\n|\n|\nBuenas pr\u00e1cticas cl\u00ednicas (GCP) en Am\u00e9rica Latina: Perspectivas de harmonizaci\u00f3n regional. Un desaf\u00edo para el siglo XXI\nB\u00e9rgamo N, De Trespalacios V, M\u00e1rquez ML, P\u00e9rez S, Samaniego S, y Vander Elst E\nBolet\u00edn de informaci\u00f3n sobre F\u00e1rmacos 2001; 35:27-34\n|\n|\nEvaluaci\u00f3n de las caracter\u00edsticas del retiro por razones de seguridad del mercado mundial de f\u00e1rmacos que requieren prescripci\u00f3n \u2013 1960 a 1999\nFung M, Thornton A, Mybeck K, Hsiao-Hui W, Hornbuckle K y Mu\u00f1iz E.\nBolet\u00edn de Informaci\u00f3n sobre F\u00e1rmacos 2001; 35: 293-317\n|\n|\nRegulaci\u00f3n de la promoci\u00f3n farmac\u00e9utica en el siglo XXI\nMorris LA y Pines Apco WL\nBolet\u00edn de Informaci\u00f3n sobre F\u00e1rmacos 2000; 34: 861-873\n|\n|\nLa teratogenia de los anticonvulsivos (The teratogenicity of anticonvulsant drugs).\nHolmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM y Ryan LM\nThe New England Journal of Medicine 2001; 344 (15): 1132-8\n|\n|\nAvances m\u00e9dicos: contracepci\u00f3n oral y el riesgo de trombosis venosa (Medical Progress: oral contraceptives and the risk of venous thrombosis)\nVandenbroucke JP, Rosing J, Bloemenkamp KWM, Middeldorp S, Helmerhost FM, Bouma BN y Rosendaal FR\nThe New England Journal of Medicine 2001, 344 (20): 1527-1535\n|\n|\nRecetas de psicotr\u00f3picos potencialmente inapropiados a los adultos mayores en las consultas ambulatorias (Prescribing potentially inappropraite psychotropic medications to the ambulatory elderly)\nMort JR y Aparasu RR\nArchives of Internal Medicine 2000; 160 (18) 2825-2831\n|\n|\nLa receta de antibi\u00f3ticos en casos de infecci\u00f3n aguda de nariz o de senos: \u00bfLa determina los h\u00e1bitos personales del prescriptor? (Antibiotic prescribing in acute infections of the nose or sinuses: a matter of personal habit?)\nDe Sutter AI, De Meyere MJ, De Maeseneer JM y Peersman WP\nFamily Practice 2001; 18 (2): 209-213\n|\n|\nEl reto de la malaria resistente a la cloroquina en \u00c1rica subsahariana (The challenge of chloroquine-resistant malaria en sub-Saharan Africa)\nNuwaha F\nHealth Policy and Planning 2001; 16 (1): 1-12\n|\n|\nEnsayo escoc\u00e9s con tamoxifeno como coadyuvante: un estudio aleatorio a los 15 a\u00f1os de seguimiento (Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years)\nStewart HJ, Prescott RJ, Patrick A y Forrest M\nJournal of the National Council Institute 2001; 93 (6):456-462\n|\n|\nLa administraci\u00f3n de vitamina E y la reversi\u00f3n de los s\u00edntomas neurol\u00f3gicos de la malnutrici\u00f3n proteino-cal\u00f3rica (Vitamin E administration and reversal of neurological deficits in protein-energy malnutrition)\nKalra V, Grover JK, Ahuja GK, Rathi S, Gulati S y Kalra N\nJournal of Tropical Pediatrics 2001; 47: 39-45\n|\n|\nSeguridad y generaci\u00f3n de inmunidad despu\u00e9s de la administraci\u00f3n de la vacuna PRP-T asociada o combinada con la vacuna contra la difteria, el t\u00e9tano, y la tosferina en los ni\u00f1os tailandeses (Safety and immunogenicity of combined or associated administration of PRP-T vaccine with diphteria, tetaus and pertussis vaccine in Thai children)\nLolekha S, Hiranchote A y Simasathien S\nJournal of Tropical Pediatrics 2001; 47: 24-29\n|\n|\nTratamiento con dosis altas de IVIG en la ictericia hemol\u00edtica neonatal (Multiple dose IVIG treatment in neonatal immune hemolytic jaundice)\nTanyer G, Siklar Z, Dallar Y, Yildirmak Y y Tiras U\nJournal of Tropical Pediatrics 2001; 47: 5-53\n|\n|\nNuevas formas de tratamiento de la migra\u00f1a pedi\u00e1trica: una revisi\u00f3n de la literatura (New avenues in treatment of paediatric migraine: a review of the literature)\nPakalnis A\nFamily Practice 2001; 18:101-106.\n|\n|\nTratamiento corto del paciente esquizofr\u00e9nico internado (Short-term inpatient pharmacotherapy of schizophrenia)\nOsser DN y Sigadel R\nHarvard Review Psychiatry 2001; 9: 89-104\n|\n|\nMedici\u00f3n de desempe\u00f1o m\u00e9dico para esquizofrenia: adherencia a la prescripci\u00f3n de la dosis recomendada de antisic\u00f3ticos (Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose)\nOwen RR, Thrush CR, Kirchner JE, Fischer EP y Booth BM\nInternational Journal for Quality in Health Care 2000; 12 (6): 475-482\n|\n|\nUso inapropiado de los diur\u00e9ticos glomerulares en el paciente mayor (Inappropriate use of loop diuretics in elderly patients)\nKelly J y Chambers J\nAge and Ageing 2000; 29: 489-493\n|\n|\nLa aceptabilidad del tratamiento corto con rifampicina y pirazinamida en los pacientes con tuberculosis latente que est\u00e1n encarcelados (Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates)\nBock NN, Rogers T, Tapia JR, Herron GD, DeVoe B y Geiter LJ\nChest 2001; 119 (3): 833-837\n|\n|\nComparaci\u00f3n del tiempo de estad\u00eda hospitalaria de pacientes con sospecha de infecci\u00f3n o infecci\u00f3n confirmada por especies de estafilococo resistente a la meticilina tratados con linezolid o con vancomicina: un estudio multic\u00e9ntrico aleatorio (Comparison of length of hospital stay for patients with known or suspected methicillin-resistent staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial)\nLi Z, Willke RJ, Rittenhouse BE, Pleil AM, Hafkin B, Crouch ChW, Pinto LA, Rybak MJ y Glick HA.\nPharmacotherapy 2001; 21(3): 263-274\n|\n|\nEl control del coste de las medicinas en Canad\u00e1. \u00bfFunciona? (Pharmaceutical Cost Control in Canada: Does it work?)\nMenon D\nHealth Affairs 2001; 20 (3): 92-103\n|\n|\nDudas del p\u00fablico sobre la seguridad de la vacunaci\u00f3n y la resistencia a las vacunas (Public doubts about vaccination safety and resistance against vaccination)\nStreefland PH\nHealth Policy 2001;55:159-172\n|\n|\nLas decisiones en la consulta: decidir no vacunar \u00bfest\u00e1n los padres tomando decisiones bien informadas? (Choosing not to immunize: are parents making informed decisions?)\nSporton RK y Francis S-A\nFamily Practice 2001;18(2): 181-188\n|\n|\nImpacto de las recomendaciones para suspender la dosis que se administra al nacer de la vacuna contra el virus de la hepatitis B (Impact of recommendations to suspend the birth dose of hepatitis B virus vaccine)\nOram RJ, Daum RS, Seal JB, y Lauderdale DS\nJournal of the American Medical Association 2001; 285 (14): 1874-1879\n|\n|\nInteracciones potenciales entre plantas medicinales y f\u00e1rmacos en una poblaci\u00f3n de un servicio de urgencias (Potential herb-drug interactions in an emergency department population)\nRogers EA, Gough JE y Brewer KL\nAcademic Emergency Medicine 2001;8 (5): 451\n|\n|\nTratamientos alternativos en la poblaci\u00f3n infantil (Alternative therapy in the pediatric population)\nSchier JG, Lung EA, Killian A y Diaz JE\nAcademic Emergency Medicine 2001;8 (5): 450-451\n|\n|\nLa vigilancia longitudinal del empleo de los antibi\u00f3ticos en los hospitales (Longitudinal surveillance of antibiotic use in the hospital)\nRaveh D, Levy Y, Schlesinger Y, Greenberg A, Rudensky B, y Yinnon AM\nQuarterly Journal of Medicine 2001; 94 (3): 141-152.\n|\n|\nEl c\u00f3ctel gastro-intestinal en el tratamiento de la dispepsia. Estudio cl\u00ednico aleatorio y de doble ciego. (The GI cocktail in the treatment of dyspepsia. A randomized, double-blind clinical trial)\nBerman D, Graber M, Clark P, Koslow A, Mcfadden P, Savage J y Porter R\nAcademic Emergency Medicine 2001;8 (5): 446-a\n|\n|\nLa fluvoxamina para el tratamiento de los trastornos de ansiedad en ni\u00f1os y adolescentes (Fluvoxamine for the tratment of anxiety disorders in children and adolescents)\nWalkup JT, Labellarte MJ, Riddle MA, Pine DS, Greenhill L, Klein R, Davies M, Sweeney M, Abikoff H, Hack S, Klee B, McCracken J, Bergman L, Piacentini J, March J, Compton S, Robinson J y O\u2019hara T\nNew England Journal of Medicine 2001;344 (17): 1279-1285\n|\n|\nLa resistencia neumococ\u00f3ccica: el desafio del tratamiento (Pneumococcal resistance: The treatment challenge)\nAmsden GW y Amankwa K\nAnnals of Pharmacotherapy 2001;35 (4): 480-488\n|\n|\nAn\u00e1lisis de la legislaci\u00f3n sobre la disponibilidad de opioides utilizando los criterios de la OMS y de la OICN: un estudio comparativo de 5 pa\u00edses y del estado de Texas (Legislation analysis according to WHO and INCB criteria on opioid availability: a comparative study of 5 countries and the state of Texas)\nDe Lima L, Sakowski JA, Hill CS y Bruera E\nHealth Policy 2001; 56: 99-110\n|\n|\nLa morfina produce menos na\u00fasea que la meperidina cuando se emplea como analg\u00e9sico en los servicios de urgencias (Morphine causes less nausea than meperidina when used as an analgesic in the ed)\nSilverman ME, Shih RD y Allegra J\nAcademic Emergency Medicine 2001;8 (5): 430-431\n|\n|\nEl empleo de la aspirina antes de ingresar, estando ingresados, y al dejar el hospital en pacientes diagnosticados con infarto agudo al miocardio (Aspirin use prior to arrival, in hospital, and at discharge in patients diagnosed with acute myocardial infarction)\nKozdemba T y Vasilenko IIIP\nAcademic Emergency Medicine 2001;8 (5): 555-556\n|\n|\nLos beneficios del Pravastatin sobre los eventos cardiovasculares y la mortalidad en pacientes mayores con enfermedad card\u00edaca coronaria son iguales o exceden a aquellos observados en pacientes j\u00f3venes: Resultados del estudio de l\u00edpidos (Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal or exceed those seen in younger patients: Results from the lipid trial)\nHunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G y Tonkin A\nAnnals of Internal Medicine 2001;134 (10):931-940\n|\n|\nEfecto de la hormona paratiroidea (1-34) en las fracturas y en la densidad mineral de los huesos en mujeres postmenopausicas con osteoporosis (Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis)\nNeer RM, Arnaud CD, Zanchetta JR, prince R, Gaich A, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-shalom S, Genant HK, Wang O y Mitlak BH\nNew England journal of Medicine 2001;344 (19): 1434-1441\n|\n|\nDiscrepancias raciales en los servicios de salud (Racial disparities in medical care)\nEpstein AM y Ayanian JZ\nNew England Journal of Medicine 2001;344 (19): 1471-1473\n|\n|\nPrograma de farmacia para dar de alta a los adultos mayores hospitalizados: un estudio aleatorio de casos y controles (A pharmacy discharge plan for hospitalized elderly patients \u2013 randomized controlled trial)\nNazareth I, Burton A, Shulman S, Smith P, Haines A y Timberall H\nAge and ageing 2001; (30): 33-40\n|\n|\nImpacto del programa de co-pagos para la compra de f\u00e1rmacos en el uso de medicamentos entre las personas mayores de edad (Impact of a cost-sharing drug insurance plan on drug utilization among older people)\nBlais L, Boucher J-M, Couture J, Rahme E y LeLorier J\nJournal of the American Geriatrics Society 2001;49 (4): 410-414\n|\n|\nEficiencia o igualdad en la provisi\u00f3n de medicamentos: es una cuesti\u00f3n de \u00e9nfasis (A question of emphasis: efficiency or equality in the provisi\u00f3n of pharmaceuticals)\nAlmarsd\u00f3ttir AB, Morgall JM y Bj\u00f8rnsd\u00f3ttir I.\nInternational Journal of Health Planning and Management 2000; 15:149-161\n|\n|\nEl coste para los pacientes de las medicinas prescritas con recetas (The cost of prescription medicines to patients)\nNoyce PR, Huttin C, Atella V, Brenner G. Haaijer-Ruskamp FM, Hedvall M y Mechtler R.\nHealth Policy 2000: 52: 129-145\n|\n|\nUso de plantas medicinales entre los pacientes que acuden al departamento de urgencias (Herbal use in ED patients)\nGulla J, Singer AJ y Gaspari R.\nAcademic Emergency Medicine 2001; 8: 450\n|\n|\nConsecuencias de las recetas escritas con ayuda de computadoras en errores de prescripciones en los departamentos de urgencias (The effect of computer-assisted prescription writing on emergency department prescription errors)\nBizove KE, Beckley B, McDade M, Adams A, Zechnich A y Hedges J. Academic\nEmergency Medicine 2001; 8: 499\n|\n|\nFinanciamiento de la salud por la comunidad: Los fondos de medicamentos comunales de Honduras (Financing health care at the community health level: The community drug funds of Honduras)\nFieldler JL y Wight JB.\nInternational Journal of Health Planning and Management 2000; 15: 319-340\n|\n|\nDiez recomendaciones para mejorar el uso de los medicamentos en los pa\u00edses en v\u00edas de desarrollo (Ten recommendations to improve use of medicines in developing countries)\nLaing R, Hogerzeil HV y Ross-Degnan D.\nHealth Policy and Planning 2001; 16: 13-20\n|\n|[ Fondos rotarios para medicamentos en los servicios de salud de Vientiane, Laos (Revolving drug funds at front-line health facilities in Vientiane, Lao PDR ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3888)\nMurakami H, Phommasack B, Oula R, y Sinxomphou SHealth Policy and Planning 2001; 16(1): 98-106\n|\n|[ Estrategias para reducir los costes farmac\u00e9uticos de los hospitales (Modelling strategies for reducing pharmaceutical costs in hospitals) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1e0e)\nMacintyre CR, Sindhusake D y Rubin G.International Journal for Quality in Health Care 2001; 13(1):63-69\n|\n|[Tratamiento para la depresi\u00f3n de los adultos mayores en los cuidados primarios \u2013 una revisi\u00f3n sistem\u00e1tica de la literatura (Treatments for late life depresi\u00f3n in the primary care \u2013 a systematic review) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac25c)\nFreudenstein U, Jagger C, Arthur A y Donner-Benzhoff NFamily Practice 2001; 18(3): 321-327\n|\n|[Reacciones adversas a los f\u00e1rmacos antirreum\u00e1ticos modificadores de la enfermedad en la pr\u00e1ctica cl\u00ednica(Adverse reactions to disease modifying anti rheumatic drugs in clinical practice) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaabfd)\nGrove ML, Hassell AB, Hay EM y Shadforth MFQuarterly Medical Journal 2001; 94(6): 309-319\n|\n|[El papel del farmac\u00e9utico en el manejo de las enfermedades transmitidas sexualmente (ETS): Pol\u00edticas y opciones para Ghana(Pharmacists\u00b4 role in managing sexually transmitted infections: policy issues and options for Ghana) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf490)\nMayhew S, Nzambi K, Pepin J y Adjei SHealth Policy and Planning 2001; 16(2): 152-160\n|\n|[Los fines contra los medios: El papel de los mercados en la expansi\u00f3n del acceso a los anticonceptivos. Una revisi\u00f3n de la literatura (Ends versus means: the role of markets in expanding access to contraceptives. Review Article) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9033)\nHanson K, Kumaranayake L y Thomas IHealth Policy and Planning 2001; 16(2): 125-136\n|\n|[Un an\u00e1lisis pol\u00edtico de donaciones de medicamentos hechas por la industria farmac\u00e9utica: el ejemplo de Malarone@ en Kenia (A political analysis of corporate drug donations: the example of Malorene@ in Kenya) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae1e6)\nShretta R, Walt G, Brugha R y Snow RWHealth Policy and Planning 2001; 16(2): 161-170\n|\n|[Riesgo de complicaciones cardiovasculares asociadas con inhibidores selectivos COX-2 (Risk of cardiovascular events associated with selective COX-2 inhibitors) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8584)\nMukherjee D, Niessen SE y Topol EJJournal of the American Medical Association 2001;286 (8): 954-959\n|\n|[Que sabemos sobre las estatinas: indicaciones, utilizaci\u00f3n, y preguntas que est\u00e1n todav\u00eda sin respuestas (Status of statins: indications, utilization, and unanswered questions) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista72f3)\nMalhotra S, Gover A y Munjal G. Medscape Pharmacotherapy 2 de mayo de 2001\n|\n|[\u00bfConstituye el acuerdo TRIPS de la Organizaci\u00f3n Mundial del Comercio un impedimento para el acceso a medicamentos esenciales en los pa\u00edses en v\u00edas de desarrollo? (Access to essential medicines in developing countries: does the WTO TRIPS agreement hinder it?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista72e9)\nWatal JScience, Technology and Innovation Discussion paper no. 8, Center for International Development, Harvard University. Art\u00edculo in\u00e9dito. Se puede pedir copia a\n[jwatal@iie.com](mailto:jwatal@iie.com)\n|\n|[El precio diferencial de los f\u00e1rmacos esenciales (Differential pricing of essential drugs) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3dae)\nSin autorRev Panam Salud P\u00fablica 9; 2001:275-279\n|\n|[\u00bfFunciona el control del coste de medicamentos en Canad\u00e1? (Pharmaceutical cost control in Canada: Does it work?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6214)\nMenon DHealth Affairs 2001; 20(3):92-103\n|\n|[Estudios sobre medicamentos en los pa\u00edses en v\u00edas de desarrollo (Drug studies in developing countries) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1cf0)\nOlliaro PL, Vijayan R, Inbasegaran K, Lang CC, Looareesuwan SBulletin of the World Health Organization 2001; 79(9):894-895\n|\n|[La calidad metodol\u00f3gica de los estudios de casos y controles de homeopat\u00eda, plantas medicinales y de acupuntura (The methodological quality of randomized controlled trals of homeopathy, herbal medicines and acupunture) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1945)\nLinde K, Jonas WB, Melchart D y Willich S.International Journal of Epidemiology 2001; 30 (3): 526-531\n|\n|[Efecto del carvedilol en la sobrevivencia en el fallo cardiaco cr\u00f3nico severo (Effect of carvedilol on survival in severe chronic heart failure) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae66c)\nPacker M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK y DeMets DL.New England Journal of Medicine 2001; 344(22): 1651-1658\n|\n|[La warfarina es igual a la aspirina contra el accidente cerebrovascular (Warfarina = apirin for stroke) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab90c)\nB. VastagJournal of the American Medical Association 2001; 285(23): 2966\n|\n|[El tratamiento de reemplazo hormonal y la prevenci\u00f3n de fracturas no vertebrales: Un meta-an\u00e1lisis de estudios aleatorios. (Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafacf)\nTorgerson DJ y Bell-Syer SEMJournal of the American Medical Association 2001; 285(22): 2891-2897\n|\n|[Efecto del ramipril vs amlodipina en el resultado renal en la nefrosclerosis hipertensiva: Un ensayo cl\u00ednico controlado aleatorio (Effect of ramipril vs amlodipina on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac866)\nAgodoa LY, Appel L, Bakris GL, George L, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek DA, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller, ERIII, Norris K, O\u2019Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schuleman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT, y Xu ShichenJournal of the American Medical Association 2001; 285(21): 2719-2728\n|\n|[Monoterapia con un agonista [beta]2 de larga duraci\u00f3n vs. el tratamiento continuo con corticoesteroides inhalados en pacientes con asma pesistente: Un estudio de casos y controles (Long-acting [beta]2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista55e4)\nLazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RFJr, Sorkness CA, Kraft M, Fish JE, Peters SP, Craig T;, Drazen JF, Ford JG, Israel E, Mart\u00edn RJ, Mauger EA, Nachman SA, Spahn JD, Szefler SJJournal of the American Medical Association 2001; 285(20): 2583-2593\n|\n|[Reducci\u00f3n y eliminaci\u00f3n de corticoesteroides inhalados en pacientes con asma persistente recibiendo salmeterol: Un estudio de casos y controles (Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: A randomized controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1c2a)\nLemanske RFJr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, Drazen JM, Chinchilli, VM, Craig T, Fish JE, Ford JG, Israel E, Kraft M, Martin RJ, Nachman SA y Peters SJournal of the American Medical Association 2001; 285(20): 2594-2603\n|\n|[Seguridad en las inyecciones: Resumen del panel de la conferencia del a\u00f1o 2000 sobre enfermedades infecciosas en Atlanta, Georgia (Injection safety: Panel summary from the 2000 emerging infectious diseases conference in Atlanta, Georgia) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa224)\nLuby SEmerging Infectious Diseases Journal 2001; 7(3): Supplement\n|\n|[\u00bfCu\u00e1l puede ser la consecuencia de que los planes de salud se atrasen en cubrir medicamentos nuevos? (What will be the consequences of health plans\u2019 coverage delay new drugs?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista27f6)\nDebi ReissmanDrug Benefit Trends 2001; 13(4): 44\n|\n|[Tendencias globales en resistencia a los f\u00e1rmacos antituberculosos (Global trends in resistance to antituberculosis drugs) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista254b)\nEspinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R y Raviglione MCNew England Journal of Medicine 2001; 344(17): 1294-1303\n|\n|[\u00bfEs este paciente al\u00e9rgico a la penicilina? Un an\u00e1lisis basado en la evidencia de la probabilidad de ser al\u00e9rgico a la penicilina (Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5e4e)\nSalkind AR, Cuddy PG y Foxworth JWJournal of the American Medical Association 2001; 285(19): 2498-2505\n|\n|[Inicio del uso ilegal de f\u00e1rmacos que alteran la mente o potencialmente adictivos entre farmac\u00e9uticos (Onset of illegal use of mind-altering or potentially addictive prescription drugs among pharmacist) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa084)\nDabney DAJournal of the American Pharmaceutical Association 2001; 41(3): 392-400\n|\n|[Manejo farmacol\u00f3gico de la epilepsia en los adultos mayores (Pharmacologic management of epilepsy in the elderly) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista54b9)\nBourdet SV, Gidal BE y Alldredge BKJournal of the American Pharmaceutical Association 2001; 41(3): 421-436\n|\n|[Hipotensi\u00f3n asociada con la administraci\u00f3n de acetaminof\u00e9n en pacientes severamente enfermos: \u00bfOtra raz\u00f3n para no tratar la fiebre? (Hypotension associated with acetaminophen administration in the critically ill: Another season not to treat a fever?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista175f)\nLemos JDJournal of Informed Pharmacotherapy 2001; 5: 300-305\n|\n|[Aparecen mecanismos de resistencia a las fluoroquinolonas (Emerging machanisms of fluoroquinolone resistence) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista964a)\nHooper DCCDC Emerging Infectious Diseases 2001; 7(2)\n|\n|[Administraci\u00f3n postnatal de zidovudina para la prevenci\u00f3n de la transmisi\u00f3n vertical del VIH-1 en un hospital (Postnatal zidovudine in prevention of vertical HIV-1 transmission in a service setting) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8675)\nRabie H, Pieper CH, Robson B y Cotton MFJournal of Tropical Pediatrics 2001; 47(7): 215-219\n|\n|[Las plantas medicinales y el cuidado perioperatorio (Herbal medicine and perioperative care) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1e0e-2)\nAng-Lee MK, Moss J y Yuan C-SJournal of the American Medical Association 2001; 286(2): 208-216\n|\n|[Las ciberfarmacias y el papel de la FDA (Cyberpharmacies and the role of the US Food and Drug Administration) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2861)\nHenney JEJournal of Medical Internet Research 2001; 3(1): e3\n|\n|[Antihistam\u00ednicos de segunda generaci\u00f3n: El debate de los que se venden sin receta (Second-generation antihistamines: The OTC debate) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae9bf)\nSampey CS y Follin SLJournal of the American Pharmaceutical Association 2001; 41(3): 454-457\n|\n|[Reconociendo, informando y reduciendo las reacciones adversas de los f\u00e1rmacos (Recognizing, reporting, and reducing adverse drug reactions) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6969)\nBrown SDJr y Landry FJSouthern Medical Journal 2001; 94(4): 370-373\n|\n|[Errores de medicaci\u00f3n y reacciones adversas a los f\u00e1rmacos en pacientes pedi\u00e1tricos hospitalizados (Medication errors and adverse drug events in pediatric inpatients) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2fc9)\nCausal R, Bates DW, Landrigan C, Mckenna KJ, Clapp MD, Federico F y Goldmann DAJournal of the American Medical Association 2001; 285(16): 2114-2120\n|\n|[Errores de medicaci\u00f3n, desaf\u00edos en farmacolog\u00eda pedi\u00e1trica: Minimizando los errores de medicaci\u00f3n (Medication errors, challenges in pediatric pharmacotherapy: Minimizing medication errors) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistacb36)\nMitchell ALMedscape Pharmacist, 2001\n|\n|[Informe del grupo de trabajo sobre la hipertensi\u00f3n en el embarazo (Working group report on high blood pressure in pregnancy) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac4a6)\nJournal of Clinical Hypertension 2001; 3(2): 75-88\n|\n|[Tratamiento de la leishmaniasis visceral de India con infusiones \u00fanicas o diarias de amfotericina liposomal B a dosis bajas: Estudio cl\u00ednico aleatorio (Treatment of indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: Randomised trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9e6d)\nSundar S, Agrawal G, Rai M, Makharia MK y Murray HWBritish Medical Journal 2001; 323(7310): 419-422\n|\n|[Aumento de las necesidades de tiroxina en las mujeres hipotiroideas que reciben tratamiento con estr\u00f3genos (Increased need for thyroxine in women with hypothyroidism during estrogen therapy) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae76e)\nArafah BMNew England Journal of Medicine 2001; 344(23): 1743-1749\n|\n|[El impacto de la fortificaci\u00f3n de los alimentos de los EE.UU. con \u00e1cido f\u00f3lico en la incidencia de defectos del tubo neural (Impact of folic acid fortification of the US food supply on the ocurrence of neural tube defects) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3fb3)\nHonein MA, Paulozzi LJ, Mathews TJ, Erickson JD y Lee-Yang CJournal of the American Medical Association 2001; 285(23): 2981-2986\n|\n|[El efecto de la suplementaci\u00f3n con zinc en la incidencia de malaria y otras causas de morbilidad en los ni\u00f1os en \u00c1frica Occidental: Estudio aleatorio, a doble ciego y controlado con placebo (Effect of zinc supplementation on malaria and other causes of morbidity in west african children: randomised double blind placebo controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7400)\nMuller O, Becher H, Baltussen VZA, Ye Y, Diallo DA, Konate AT, Gbangou A, Kouyate B y Garenne MBritish Medical Journal 2001; 322: 1567\n|\n|[La morbilidad y la mortalidad relacionada con los f\u00e1rmacos: Actualizando el modelo del costo de la enfermedad (Drug-related morbidity and mortality: Updating the cost-of-illness model) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaedbf)\nErnst FR y Grizzle AJJournal of the American Pharmaceutical Association 2001; 41(2): 192-199\n|\n|[Impacto econ\u00f3mico de la resistencia a los antimicrobianos (Economic Impact of Antimicrobial Resistance) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista877b)\nMc. Gowan, JECDC Emerging Infectious Diseases, 2001, 7 (2)\n|\n|[Inyecciones con corticoides en las lesiones de tendones (Corticosteroid injections in tendon lesions) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista938f)\nSpeed CABritish Medical Journal 2001; 323:382-6\n|\n|[Corticosteroides de absorci\u00f3n lenta para las alergias y necrosis avascular de las caderas (Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1473)\nNasser SMS y Ewan PWBritish Medical Journal 2001; 322:1589-1591\n|\n|[Mecanismos de control de la resistencia a los antimicrobianos en los hospitales: Control de infecciones y el uso de antibi\u00f3ticos (Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2ee5)\nWeinstein RACDC Emerging Infectious Diseases 2001; 7 (2)\n|\n|[Errores de medicaci\u00f3n relacionados con problemas en la formulaci\u00f3n de las dosis (Medication errors related to dosage formulation issues) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0902)\nLesar TSMedscape Pharmacists, 28 de agosto de 2001\n|\n|[Amodiaquina, sulfadoxina/pirimetamina, y terapia combinada para el tratamiento de malaria falciparum no complicada en Kampala, Uganda: un ensayo cl\u00ednico aleatorio (Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafbfe)\nStaedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, y Rosenthal PJLancet 2001; 358:368-74\n|\n|[Comparaci\u00f3n entre la primera y segunda l\u00ednea de antibi\u00f3ticos para el tratamiento de la sinusitis aguda simple](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista54f9)\n(Impact of First-Line vs Second-Line Antibiotics for the Treatment of Acute Uncomplicated Sinusitis)\nPiccirillo JF, Mager DE, Frisse ME, Brophy RH y Goggin AJAMA 2001;286:1849-1856\n|\n|[Terapia de baja dosis de prednisone para pacientes con artritis reumatoide activa incipiente: eficacia cl\u00ednica, propiedades modificadoras de la enfermedad y efectos secundarios: ensayo cl\u00ednico controlado, aleatorio, a doble ciego (Low-dose prednisone therapy for patients with early active rheumatoid artritis: clinica efficacy, diesease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec3a)\nvan Everdingen AA,. Jacobs JWG, Siewertsz van Reesema DR, y Bijlsma JWJAnnals of Internal Medicine 2002; 136(1)\n|\n|[Perfil de riesgos beneficios de terapias de plantas medicinales de uso com\u00fan: Ginkgo, Hierba de San Juan, Ginseng, Echinacea, Saw Palmetto y Kava (The Risk-Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John\u2019s Wort, Ginseng, Echinacea, Saw Palmetto, and Kava) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0625)\nErnst EAnnals of Internal Medicine 2002; 136 (1): 42-53\n|\n|[AINES: Nuevos tipos de aspirina disfrazada ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf3f3)\nAIS-CODECO-IBFAN-FUNAVI BOLIVIA Bolet\u00edn No. 118 Vol. XV No. 3 Abril \u2013 Mayo 2001\n|\n|[Acetaminofen, aspirina y fallo renal cr\u00f3nico (Acetaminophen, Aspirin, and Chronic Renal Failure) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0ac0)\nFored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman, PW, Signorello LB, Lipworth L, Elinder CG, Blot WJ,. McLaughlin J K, Zack MM y Nyr\u00e9n ONew England Journal of Medicine 2001; 345 (25): 1801-1808\n|\n|[Inhibidores de cyclooxygeinasa y los efectos antiplaquetarios de la aspirina (cyclooxygenase inhibitors and the antiplatelet effects of aspirin) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8678)\nCatella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, y FitzGerald GANew England Journal of Medicine 2001; 345 (25):1809-1817\n|\n|[Estudio cl\u00ednico de 32 pacientes con reacciones inducidas por diclofenaco ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista851a)\nMart\u00edn E, G\u00f3mez A, Hinojosa B, S\u00e1enz de San Pedro B, Florido F y Quiralte JAlergol Inmunol Cli 2001; 16: 202-208\n|\n|[El mercado de gen\u00e9ricos en Espa\u00f1a y en USA: \u00bfPor qu\u00e9 tantas diferencias? ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaea81)\nde la Lama Rinc\u00f3n JMVII Congreso Galaico-Cubano de Salud P\u00fablica\n|\n|[Impacto del costo de medicamentos de prescripci\u00f3n en los resultados cl\u00ednicos de pacientes indigentes con enfermedades cardiacas (Impact of the cost of prescription grugs on clinical outcomes in indigent patients with heart disease) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2b02)\nSchoen Marieke D, DiDomenico RJ, Connor SE, Dischler JE, y Bauman JLPharmacotherapy 2001; 2(12):1455-1463\n|\n|[Medicina tradicional en el Per\u00fa: Actividad antimicrobiana in vitro de los aceites esenciales extra\u00eddos de algunas plantas arom\u00e1ticas ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista77e9)\nAlzamora L, Morales L, Armas L, Fern\u00e1ndez GAnales de la Facultad de Medicina Universidad Nacional Mayor de San Marco 2001; 62(2)\n|\n|[Estudio prospectivo de seguridad de inmunoterapia agrupada con extractos acuosos de p\u00f3lenes ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3c7c)\nMoreno C, Fern\u00e1ndez-T\u00e1vora L, Vidal C, Justicia JL y Guerra FAlergol Inmunol Clin 2001:16: 95-101\n|\n|[Prescripci\u00f3n racional y reducci\u00f3n de costes en el tratamiento de la hipertensi\u00f3n arterial: un ejercicio de simulaci\u00f3n ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista629c)\nBoneta A, Gosalbesb V, Fitoc M, Navarro JGaceta Sanitaria 2001; 15(4): 327-335\n|\n|[Ranitidina y alteraciones electrocardiogr\u00e1ficas en ni\u00f1os ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec61)\nRam\u00edrez MJA, Garrido GLM, Villalobos CCE, Mason CT, et alRev Alerg Asma Inmunol Pediatr 2001; 10 (2): 40-42\n|\n|[Respuesta al tratamiento de la bronquiolitis con epinefrina natural (lev\u00f3gira) inhalada ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista86ae)\nMart\u00ednez-Jim\u00e9nez NB, Maza-Toledo AA, L\u00f3pez-Jim\u00e9nez C y Ortiz-M\u00e9ndez VMRev Mex Pediatr 2001; 68 (1): 5-7\n|\n|[T\u00e9cnica inadecuada en el empleo de inhaladores en pacientes atendidos en una consulta de neumolog\u00eda ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7f43)\nGolpe G\u00f3mez R, Mateos Colmo A y Soto Franco IAnales de Medicina Interna 2001; 18(2)\n|\n|[Uso de plantas nativas para mejorar el bienestar: un estudio en la Rep\u00fablica Sudafricana (Use of indiginous and indigenised medicines to enhance personal well-being: a South African case study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8e77)\nCocks M y M\u00f8oller VSocial Science and Medicine 2002; 54 (3): 387-397\n|\n|[\u00bfLas pol\u00edticas nacionales de medicamentos y los programas de medicamentos esenciales mejoran el uso de los medicamentos?: Una revisi\u00f3n de las experiencias en pa\u00edses en v\u00edas de desarrollo (Do national medicinal drug policies and essential drug programs improve drug use?: a review of exeperiences in developing countries) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1e3e)\nRatanawijitrasin S, Soumerai SB y Weerasuriya KSocial Science and Medicine 2001; 53: (7): 831-844\n|\n|[Estrategias econ\u00f3micas y financiamiento del medicamento ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab4aa)\nTobar F y Godoy Garraza LCuadernos M\u00e9dicos Sociales (Argentina) 2001; 80: 67-91\n|\n|[Estudio de la utilizaci\u00f3n de ticlopidina en oficinas de farmacia de Espa\u00f1a ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista23c9)\nDel Pino AM, de Abajo FJ, Montero D, Madurga M y Mart\u00edn-Serrano GMedicina Cl\u00ednica (Barcelona) 2000; 115 (6): 211-213\n|\n|[La profilaxis con fluconazole para prevenir la colonizaci\u00f3n y las infecciones mic\u00f3ticas en neonatos prematuro (Fluconazole prophylaxis against fungal colonization and infection in preterm infants) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8788)\nKaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M y Donowitz LGNew England Journal of Medicine 2001; 345(23): 1660-1666\n|\n|[Comparaci\u00f3n de la efectividad del tratamiento antituberculoso de corta duraci\u00f3n de la OMS y de los reg\u00edmenes est\u00e1ndar rusos en Tomsk, Siberia occidental (Comparison of the effectiveness of WHO short-course chemotherapy and standard Russian antituberculous regimens in Tomsk, western Siberia) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7737)\nMawer C, Ignatenko NV, Wares DF, Strelis AK, Golubchikova VT, Yanova GV, Lyagoshina TV, Sharaburova OE y BanatvalaLancet 2001; 358: 445-449\n|\n|[Efecto de la restricci\u00f3n del contacto entre los representantes de las compa\u00f1\u00edas farmac\u00e9uticas y de los residentes de medicina interna en las actitudes y comportamiento despu\u00e9s del entrenamiento (Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab999)\nMcCormick BB, Tomlinson G, Brill-Edwards P y Detsky ASJournal of the American Medical Association 2001; 286(16): 1994-1999\n|\n|[\u00bfLas patentes de los medicamentos antiretrovirales restringen el acceso al tratamiento del SIDA en \u00c1frica? (Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1304)\nAttaran A y Gillespie-White LJournal of the American Medical Association 2001; 286(15): 1886-1892\n|\n|[Comparaci\u00f3n del tratamiento prenatal de la mujer a riesgo de parto prematuro con corticosteroides en dosis \u00fanica y semanal (Single vs. weekly courses of antenatal corticosteroids for women at risk of preterm delivery) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista73a0)\nGuinn DA, Atkinson MW, Sullivan L, Lee MJ, MacGregor S, Parilla BV, Davies J, Hanlon-Lundberg K, Simpson L, Stone J, Wing D, Ogasawara K y Muraskas JJournal of the American Medical Association 2001; 286(13): 1581-1587\n|\n|[Efecto del losartan sobre el ri\u00f1on y el sistema cardiovascular en pacientes con diabetes tipo 2 y con nefropat\u00eda (Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0a47)\nBrenner BM, Cooper ME, Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z y Shahinfar S., investigadores del estudio RENAAL.New England Journal of Medicine 2001; 345(12): 861-869\n|\n|[Efecto protectivo sobre el ri\u00f1\u00f3n del irbesartan, antagonista de los receptores de la angiotensina, en pacientes con nefropat\u00eda debida a diabetes tipo 2 (Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9eda)\nLewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R y Raz I., para grupo colaborador en el estudioNew England Journal of Medicine 2001; 345(12): 851-860\n|\n|[El efecto del irbesartan en el desarrollo de la nefropat\u00eda dib\u00e9tica en pacientes con diabetes tipo 2 (The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8a8f)\nParving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S y Arner P., para el grupo de estudio de los pacientes con irbesartan con diabetes tipo 2 y micro albuminuriaNew England Journal of Medicine 2001; 345(12): 870-878\n|\n|[Tratamiento m\u00e9dico de la neurocisticercosis caracterizada por grandes quistes subaracnoideos (Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad853)\nProa\u00f1o JV, Madrazo I, Avelar F, L\u00f3pez-F\u00e9lix B, D\u00edaz G y Grijalva INew England Journal of Medicine 2001; 345(12): 879-885\n|\n|[Alergia a las cefalosporinas (Cephalosporin allergy) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista233e)\nKelkar PS y Li JTCNew England Medical Journal 2001; 345(11): 804-809\n|\n|[Cambiando el status de los medicamentos: de precisar receta a ser de venta libre (Changing the status of drugs from prescription to over-the-counter availability) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista37d0)\nBrass EPNew England Journal of Medicine 2001; 345(11): 810-816\n|\n|[Amplia distribuci\u00f3n de infecciones del tracto urinario causadas por un grupo clonal de Escherichia coli resistente a varios medicamentos (Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9257)\nManges AR, Jonson JR, Foxman B, O\u2019Bryan TT, Fullerton KE y Riley LWNew England Journal of Medicine 2001; 345(14): 1007-1013\n|\n|[Vacunas y vacunaciones (Vaccines and vaccinations) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf10e)\nAda, GNew England Journal of Medicine 2001; 345(14): 1042-1053\n|\n|[Efectos a largo plazo de la profilaxis con indometacina en ni\u00f1os con peso al nacer extremadamente bajo (Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista89a4)\nSchmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, Solimano A, Vincer M y Wright LLNew England Journal of Medicine 2001; 344(26): 1966-1972\n|\n|[La comparaci\u00f3n del lorazepam, diazepam y placebo para el tratamiento de los ataques epil\u00e9pticos en pacientes no hospitalizados (A comparison of lorazepam, diazepam, y placebo for the treatment of out-of-hospital status epilepticus) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa24b)\nAlldredge BK, Gelb AM, Isaacs M, Corry MD, Allen F, Ulrich SK, Gottwald MD, O\u2019Neil N, Neuhaus JM, Segal MR y Lowenstein DHNew England Journal of Medicine 2001; 345(9): 631-637\n|\n|[La comparaci\u00f3n del ligado endosc\u00f3pico con el tratamiento combinado de nadolol y mono nitrato de isosorbide para prevenir el sangrado recurrente de las varices (Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1557)\nVillanueva C, Mi\u00f1ana J, Ortiz J, Gallego A, Soriano G, torras X, S\u00e1inz S, Boadas J, Cuss\u00f3 X, Guarner C y Balanz\u00f3 JNew England Journal of Medicine 2001; 345(9): 647-655\n|\n|[Falla del metronidazol para prevenir el parto prematuro en mujeres embarazadas con infecci\u00f3n asintom\u00e1tica de Trichomonas vaginalis (Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa73f)\nKlebanoff MA, Carey JC, Hauth. JC, Hillier SL, Nugent RP, Thom EA, Ernest JM, Heine RP, Wapner RJ, Trout W, Moawad A y Leveno KJNew England Journal of Medicine 2001; 345(7): 487-493\n|\n|[La din\u00e1mica de la tuberculosis en respuesta a 10 a\u00f1os de esfuerzo intensivo de control en Per\u00fa (The dynamics of tuberculosis in response to 10 years of intensive control effort in Per\u00fa) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafeb1)\nSu\u00e1rez PG, Watt CJ, Alarc\u00f3n E, Portocarrero J, Zavala D, Canales R, Luelmo F, Espinal MA y Dye CJournal of Infectious Diseases 2001; 184: 473-478\n|\n|[Efectos del clopidogrel junto con la aspirina en los pacientes con s\u00edndrome coronario agudo sin elevaci\u00f3n del segmento ST (Effects of clopidogrel in addition to aspirin in patients with acute coronary s\u00edndromes without ST \u2013 segments elevation) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac272)\nLos investigadores del estudio del clopidogrel en la angina inestable para prevenir eventos recurrentes.New England Journal of Medicine 2001; 345(7): 494-502\n|\n|[Puesta al d\u00eda: lesiones hep\u00e1ticas mortales asociadas con el rifampin y la pirazinamida para el tratamiento de la tuberculosis latente y revisiones de la sociedad tor\u00e1cica americana y las recomendaciones del centro para el control de las enfermedades de los EE.UU., 2001 (Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC Recommendations-United States, 2001) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista488a)\nMMWR 2001; 50:733-735.\n[http://www.cdc.gov/mmwr](http://www.cdc.gov/mmwr)\n|\n|[Efecto de un tratamiento corto con una dosis alta de amoxicilina en los portadores de neumococos resistentes (Effect of short-course, high-dose amoxicillin therapy on resistent pneumococcal carriage) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad186)\nSchrag SJ, Pe\u00f1a C, Fern\u00e1ndez J, S\u00e1nchez J, G\u00f3mez V, P\u00e9rez E, Feris JM y Besser REJournal of the American Medical Association 2001; 286(1): 49-56\n|\n|[Amodiaquina, sulfadoxina/pirimetamina y la terapia combinada para el tratamiento de la malaria falciparum sin complicaciones en Kampala, Uganda: ensayo aleatorio. (Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7ae6)\nStaedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED y Rosenthal PJLancet 2001; 358: 368-374\n|\n|[El tratamiento de la malaria falciparum resistente con dapsona-cloroproguanil en Tanzania (Chloproguanil-dapsone for treatment of drug-resistent falciparfum malaria in Tanzania) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3b59)\nMutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E y Watkins WLancet 2001; 358: 1218-1223\n|\n|[Tratamiento de la tuberculosis resistente a varios f\u00e1rmacos en Turqu\u00eda (The treatment of multidrug-resistant tuberculosis in Turkey) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista963d)\nTahaoglu K, T\u00f6r\u00fcn T, Sevim T, Ata\u00e7 G, Kir A, Karasulu L, \u00d6zmen I y Kapakli NNew England Journal of Medicine 2001; 345(3): 170-174\n|\n|[Tratamiento de la endometriosis (Treatment of endometriosis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5839)\nOlive DL y Pritts EANew England Journal of Medicine 2001; 345(4): 266-275\n|\n|[Profilaxis medicamentosa contra el c\u00e1ncer del seno (Chemoprevention of breast cancer) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae241)\nLevine M, Moutquin J-M, Walton R y Feightner JCanadian Medical Association Journal 2001; 164(12): 1681-1690\n|\n|[\u00bfCu\u00e1l es la calidad de las indicaciones de la terapia medicamentosa para la pr\u00e1ctica cl\u00ednica en Canad\u00e1? (What is the quality of drug therapy clinical practice guidelines in Canada?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8c15)\nGraham ID, Beardall S, Carter AO, Glennie J, H\u00e9bert PC, Tetroe JM, McAlister FA, Visentin S y Anderson GMCanadian Medical Association Journal 2001; 165(2): 157-163\n|\n|[Impacto de utilizar precios de referencia para los nitratos en el uso y costo de los medicamentos contra la angina (Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7492)\nGrootendorst PV, Dolovich LR, O\u2019Brien BJ, Holbrook AM y Levy ARCanadian Medical Association Journal 2001; 165(8): 1011-1019\n|\n|[La simvastatina y la niacina, vitaminas antioxidantes o su combinaci\u00f3n para la prevenci\u00f3n de la enfermedad coronaria (Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaac5f)\nBrown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J y Albers JJNew England Journal of Medicine 2001; 345(22): 1583-1592\n|\n|[El fenoldopam un agonista de los receptores perif\u00e9ricos selectivos de la dopamina para el tratamiento de la hipertensi\u00f3n severa (Fenoldopam \u2013 a selective peripheral dopamine \u2013 receptor agonista for the treatment of severe hipertensi\u00f3n) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2fa1)\nMurphy MB, Murria C y Sorteen GDNew England Journal of Medicine 2001; 345(21): 1548-1557\n|\n|[Reversi\u00f3n del catabolismo por bloqueo-beta despu\u00e9s de quemaduras severas (Reversal of catabolism by beta-blockade after severe burns) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3877)\nHerdon DN, Hart DW, Wolf SE, Chinkes DL y Wolfe RRNew England Journal of Medicine 2001; 345(17): 1223-1229\n|\n|[Estudio aleatorio del bloqueador de los receptores de angiotensina valsartan en el fallo card\u00edaco cr\u00f3nico (A randomized trial of the angiotensin-receptor blocker valsartan in chronic Herat failure) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae465)\nCohn JN y Tognoni G, investigadores del estudio del valsartan en el fallo card\u00edacoNew England Journal of Medicine 2001; 345(23): 1667-1675\n|\n|[Plantas medicinales para la menopausia: \u00bfSon efectivas y seguras? (Herbal medicines for menopause: do they work and are they safe?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafba0)\nEden JAMedical Journal of Australia 2001; 174: 63-64\n|\n|[Benztropina para el espasmo muscular agudo en el departamento de emergencias (Benztropine for acute muscle spasm in the emergency department) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf0b9)\nEpstein NLCanadian Medical Association Journal 2001; 164(2): 203-204\n|\n|[Estudio del t\u00e9 Oolong en el manejo de la dermatitis at\u00f3pica recalcitrante (A Trial of Oolong Tea in the Management of Recalcitrant Atopic Dermatitis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1b1c)\nUehara M, Sugiura H, y Sakurai KArchives of Dermatology 2001; 137 (1): 42-43\n|\n|[Integridad de los reportes de seguridad en ensayos cl\u00ednicos aleatorios, evaluaci\u00f3n de 7 \u00e1reas m\u00e9dicas (Completeness of safety reporting in randomized trials, an evaluation of seven medical areas) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6120)\nIoannidis JP, Lau JJAMA 2001; 285 (4): 437-443\n|\n|[Efectos neuropsicol\u00f3gicos de la epilepsia y los f\u00e1rmacos anti-epil\u00e9pticos(Neuropsychological effects of epilepsy and antiepileptic drugs) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafe13)\nKwan P, Brodie MJThe Lancet 2001; 357: 216-22\n|\n|[El aborto con Mifepristone fuera del hospital acad\u00e9mico urbano en India(Mifepristone abortion outside the urban research hospital setting in India) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista91d8)\nKurus Coyaji, Batya Eliu et al.The Lancet 2001; 357: 120-121\n|\n|[Estrategia para hacer modelos de reducci\u00f3n de costes farmac\u00e9uticos en el hospital (Modelling strategies for reducing pharmaceutical costs in hospital) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista72c2)\nMacIntyre CD, Sinduysake D y Rubin GInternational Journal for Quality in Health Care 2001; 13: 63-69\n|\n|[Medici\u00f3n de la pr\u00e1ctica cl\u00ednica en la esquizofrenia: adhesi\u00f3n a las gu\u00edas de dosificaci\u00f3n de antipsic\u00f3ticos (Performance measurements for schizophrenia: adherence to guidelines for antipsychotic dose) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7728)\nOwen RR, Thrush CR, Kirchner JE, Fischer EP y Booth BMInternational Journal for Quality in Health Care 2000; 12: 475-482\n|\n|[Misoprostol y el embarazo (Misoprostol and pregnancy ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista22b5)\nGolberg AB, Greenberg MB y Darney PDNew England Journal of Medicine 2001; 344(1): 38-47\n|\n|[Efectos indeseables asociados al uso temprano de la dexametasona en ni\u00f1os de muy bajo peso al nacer(Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista60cd)\nStark AR, Carlo WA, et al.New England Journal of Medicine 2001; 344 (2): 95-101\n|\n|[Quimioprofilaxis antiplaquetaria para la prevenci\u00f3n de la oclusi\u00f3n vascular y la muerte (Antiplatelet chemoprevention of occlusive vascular events and death) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistadfad)\nTherapeutics Letter 2000; 37\n|\n|[Efectos del extracto de Ginseng G 115 estandardizado en pacientes con bronquitis. Un estudio piloto, comparativo, aleatorio (Effects of the standardised ginseng extract G115 in patients with chronic bronquitis: A nonblinded, randomised, comparative pilot study ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8839)\nScaglione F, Weiser K y Alessandria MClinical Drug Investigation 2001; 21 (1): 41-45\n|\n|[\u00bfPor qu\u00e9 se recetan antibi\u00f3ticos a pacientes con bronquitis aguda? Un an\u00e1lisis post-intervenci\u00f3n ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaca1e)\nHueston WJ, Hopper JE, Dacus EN, Mainous AGJournal American Board of Family Practice 2000; 13(6): 398-402\n|\n|[Eficacia y tolerancia de tres reg\u00edmenes de tratamiento para erradicar el helicobacter pylori. Un ensayo cl\u00ednico multic\u00e9ntrico, a doble ciego, aleatorio (Efficacy and tolerability of three regimens for Helicobacter pylori eradication. A multicentre, double-blind, randomised clinical trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3e4e)\nBujanda L, Herrerias JM, et al.Clinical Drug Investigation 2000; 21(1): 1-7\n|\n|[Eficacia y seguridad del PEG interferon alfa-2a (40-kd) comparado con interferon alfa-2a en pacientes no cirr\u00f3ticos con hepatitis C cr\u00f3nica (Efficacy and safety of pegylated (40-Kd) interferon alfa-2a compared with interferon alfa-2a in noncirrhoric patients with chronic hepatitis C ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf97f)\nReddy KR, Wright TL, Shiffman M, et al.Hepatology 2001; 33: 433-438\n|\n|[La FDA aprueba dos medicamentos para el tratamiento de VIH: Kaletra y Trizivir (Two new agents for HIV: Kaletra nad Trizivir) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4239)\nDobkin JF.Infect Med 2000; 17 (12): 777-781\n|\n|[Atenolol y crecimiento fetal en embarazos complicados con hipertensi\u00f3n (Atenolol and fetal growth in pregnancies complicated by hipertensi\u00f3n) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista61d1)\nLydakis C, Lip GY, Beever M y Beevers DGAmerican Journal of Hypertension 1999; 12 (6):541-7\n|\n|[Descenso de la presi\u00f3n arterial media y restricciones al crecimiento fetal en la hipertensi\u00f3n gestacional: metan\u00e1lisis (Fall in mean arterial pressure and fetal growth restriction in pregnancy hipertensi\u00f3n: a meta-analysis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae255)\nVon Dadelszen P, Ornstein MP, et al.The Lancet 2000; 355(9198): 87-92\n|\n|[Cosas a tener en cuenta al seleccionar la terapia anti-hipertensiva en mujeres diab\u00e9ticas embarazadas (Selecting antihypertensive threapy in the pregnant woman with diabetes mellitus) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista369c)\nConway DL, Longer OJournal of Maternal and Fetal Medicine 2000; 9(1): 66-9\n|\n|[Efectos adversos asociados con el coste compartido en la prescripci\u00f3n de medicamentos entre personas pobres y ancianos (Adverse events associated with prescription drug cost-sharing among poor and elderly persons) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2651)\nTamblyn R, Laprise R, et al.JAMA 2001; 285 (4): 421-429\n|\n|[Interferon y ribavirin versus s\u00f3lo interferon en el re-tratamiento de hepatitis cr\u00f3nica que previamente fue refractaria al tratamiento con interferon. Un metaan\u00e1lisis de ensayos randomizados (Interferon and Ribavirin Vs Interferon alone in the re-treatment of chronic Hepatitis C previously nonresponsive to interferon) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista51cf)\nCummings K, Lee S, et al.JAMA 2001; 285 (2): 193-199\n|\n|[Desarrollo de agentes antimicrobiales en la era de enfermedades infecciosas nuevas y reemergentes, y de creciente resistencia a antibi\u00f3ticos (Development of antimicrobial agents in the era of new and reemergin infectious diseases and increasing antibiotic resistance) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae8b6)\nCassel G, Mekalanos JJAMA 2001: 285 (5): 601-605\n|\n|[Quimoprevenci\u00f3n primaria de poliposis adenomatosa familiar con Sulindac (Primary chemoprevention of familial adenomatous polyposis with Sulindac) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac888)\nGiardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath J D, Piantadosi S, Garrett E, Geiman DE, Hubbard W,Offerhaus GJA y Hamilton SRNew England Journal of Medicine 2002; 346:1054-1059\n|\n|[Abastecimiento de medicamentos en unidades de primer nivel de atenci\u00f3n de la secretar\u00eda de salud de M\u00e9xico ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab3f8)\nG\u00f3mez-Dant\u00e9s O, Garrido-Latorre F, Tirado-G\u00f3mez LL, Ram\u00edrez D, Mac\u00edas CSalud P\u00fablica de M\u00e9xico 2001; 43 (3): 224-232\n|\n|[Ingesta de calcio y riesgo de c\u00e1ncer de colon en hombres y mujeres (Calcium Intake and Risk of Colon Cancer in Women and Men) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista098f)\nWu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci ELJournal of the National Cancer Institute 2002; 94 (6): 437-446\n|\n|[Las relaciones entre los autores de las gu\u00edas de pr\u00e1ctica cl\u00ednica y la industria farmac\u00e9utica (Relationships between authors of clinical practice guidelines and the pharmaceutical industry) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae80c)\nChoudhry NK, Stelfox HT y Detsky ASJAMA 2002; 287:612-617\n|\n|[La heparina de bajo peso molecular (HBPM) es tan efectiva en prevenir la recidiva de enfermedad tromboemb\u00f3lica como los anticoagulantes orales aunque mucho m\u00e1s cara ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad73c)\nCochrane Database Syst Rev. 2002;(1):CD002001\n|\n|[Consumo de pescado y \u00e1cido graso Omega-3 y riesgo de cardiopat\u00eda isqu\u00e9mica entre mujeres (Fish and Omega-3 fatty acid intake and risk of coronary heart disease in women) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3011)\nHu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode MK, Albert CM, Hunter D, Manson JAEJAMA 2002; 287 (14):1815-1821\n|\n|[Efecto del perforato hyp\u00e9rico (St John\u2019s Wort ) en el desorden depresivo grave: ensayo cl\u00ednico controlado aleatorio (Effect of Hypericum perforatum [St John\u2019s Wort] in major depressive disorder. A ramdomized controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabe85)\nHypericum Depression Trial Study GroupJAMA 2002; 287 (14):1807-1814\n|\n|[Tratamiento de espondilitis anquilopoy\u00e9tica activa con infliximab: ensayo cl\u00ednico multic\u00e9ntrico controlado aleatorio (Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaef80)\nBraun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, S\u00f6rensen H, Zeidler H, Thriene W, Sieper JThe Lancet 2002; 359 (9313): 1187-1193\n|\n|[Eficacia de tres tratamientos cortos de zidovudina y lamivudina en prevenci\u00f3n temprana y transmisi\u00f3n lejana de VIH-1 de madre a infante en Tanzan\u00eda, Sud\u00e1frica, y Uganda (Petra study): un ensayo cl\u00ednico aleatorio, a doble ciego y controlado (Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmisi\u00f3n of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomized, double-blind, placebo-controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5a4e)\nThe Petra study teamThe Lancet 2002; 359 (9313): 1178-1186\n|\n|[Implantaci\u00f3n profil\u00e1ctica de un desfibrilador en pacientes con infarto de miocardio y reducida fracci\u00f3n de eyecci\u00f3n (Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab7b2)\nMoss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML, del Multicenter Automatic Defibrillator Implantation Trial II InvestigatorsNew England Journal of Medicine 2002; 346(12): 877-883\n|\n|[El uso de agentes reductores de l\u00edpidos, sesgos de los usuarios, y el riesgo de demencia en personas mayores no institucionalizadas (Use of lipid-lowering agents, indication bias, and the risk of of dementia in community-dwelling elderly people) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8ab7)\nRockwood K, Kirkland S, Hogan DB, Merry H, Verreault R, Wolfson C, McDowell IArchives of Neurology 2002;59:223-227\n|\n|[Perspectiva: Bisfosfonatos y Osteoporosis (Perspective: Bisphosphonates and Osteoporosis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3aa1)\nSolomon CGN Engl J Med, 2002; 346:9: 653-661\n|\n|[La vitamina C reduce el riesgo de desarrollar cataratas ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3306)\nAmerican Journal of Clinical Nutrition 2002;75:540-549\n|\n|[Mejorando la terapia de los pacientes con asma- primera parte (Improving drug therapy for patients with asthma-Part 1) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0c52)\nHerborg H, Soendergaard B, Froekjaer B, Fonnesback L, Jorgensen T, Hepler Ch, Grainger-Rousseau TJ, Ersboell BKJ Am Pharm Assoc 2001; 41 (4):539-550\n|\n|[Mejorando la terapia de los pacientes con asma- Segunda parte (Improving drug therapy for patients with asthma-Part 2) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5e67)\nHerborg H, Soendergaard B, Jorgensen T, Fonnesback L, Hepler Ch, Holst H and Froekjaer BJ Am Pharm Assoc 2001; 41(4):551-559\n|\n|[Ibuprofeno vs acetaminof\u00e9n con code\u00edna para mejorar el dolor perineal despu\u00e9s de dar a luz: un estudio aleatorio controlado (Ibuprofen versus acetaminophen with codeine for the relief of perineal pain alter childbirth: a randomized controlled trial). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista23e6)\nMeter EA, Janssen PA, Grange CS, Douglas MJCanadian Medical Association Journal 2001; 165 (9): 1203-1209\n|\n|[Una comparaci\u00f3n entre la warfarina y la aspirina par la prevenci\u00f3n de la recurrencia de accidentes cerebrovasculares (A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2169)\nMohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL. Kistler JP, Albers GW, Pettigrew LC, Adams HP, Jackson CM, Pullicino P.New England Journal of Medicine 2001; 345 (20): 1444-1451\n|\n|[Comparaci\u00f3n entre el fondaparinux y el enoxaparin en la prevenci\u00f3n del tromboembolismo venoso despu\u00e9s de la cirug\u00eda de fractura de cadera (Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism alter hip-fracture surgery) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad7f2)\nEriksson BI, Bauer KA, Lassen MR, Turpie GGAThe New England Journal of Medicine 2001; 345 (18): 1298-1304\n|\n|[Comparaci\u00f3n entre el fondaparinux y el enoxaparin en la prevenci\u00f3n del tromboembolismo venoso despu\u00e9s de la cirug\u00eda mayor electiva de rodilla (Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism alter elective major knee surgery) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1627)\nBauer KA, Eriksson BI, Lassen MR, Turpie GGAThe New England Journal of Medicine 2001; 345 (18): 1305-1310\n|\n|[Inhibidores de la glocoprote\u00edna plaquetaria IIb/IIIa en el s\u00edndrome coronario agudo: un meta-an\u00e1lisis de los ensayos cl\u00ednicos controlados (Platelet glycoprotein IIb/IIIa in acute coronary s\u00edndromes: a meta-analysis of all major randomised clinical trials). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae493)\nBoersma E, Harrington RA, Moliterno DJ, White H, Th\u00e9roux P, Van der Werf F, Torba A, Armstrong WP, Wallentin LA, Wilcox RG, Simes J, Califa RM, Topol EJ, Simoons MLThe Lancet 2002; 359:189-198\n|\n|[Efectividad similar de la paroxetina, fluoxetina y la sertralina en la atenci\u00f3n primaria, estudio aleatorizado (Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care, a randomized trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae40d)\nKroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou X-H, Hays R y Weinberger M.Journal of the American Medical Association 2001; 286(23): 2947-2955\n|\n|[Interrupciones estructuradas de tratamiento para el manejo de la infecci\u00f3n con el VIH (Structured treatment interruptions for the management of HIV infection) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6598)\nLori F y Lisziewics J.Journal of the American Medical Association 2001; 286(23): 2981-2978\n|\n|[La toma de vitamina A y las fracturas de cadera en las mujeres posmenop\u00e1usicas (Vitamin A intake and hip fractures among postmenopausal women) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista84d7)\nFeskanich D, Sing V, Willett WC y Colditz GA.Journal of the American Medical Association 2002; 287(1):47-54\n|\n|[Terapia oral anti-hiperglic\u00e9mica contra la diabetes tipo 2,revisi\u00f3n cient\u00edfica (Oral antihyperglycemic therapy for type 2 diabetes, scientific review) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4e85)\nInzucchi SEJournal of the American Medical Association 2002; 287(3): 369-372\n|\n|[Terapia oral anti-hiperglic\u00e9mica contra la diabetes tipo 2, aplicaciones cl\u00ednicas (Oral antihyperglycemic therapy for type 2 diabetes, clinical applications) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3c8a)\nHolmboe ES.Journal of the American Medical Association 2002; 287(3): 373-376\n|\n|[Avances en el tratamiento de la artritis reumatoide (Progress in the treatment of rheumatoid artritis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista55f3)\nPiseysky DS y St. Clair EW.Journal of the American Medical Association 2001; 286(22): 2787-2790\n|\n|[Toma de vitamina D y riesgo de diabetes tipo 1: estudio de cohorte al nacimiento (Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3528)\nHypp\u00f6nen E, Lara E, Reunanen A, J\u00e4rvelin M-R y Virtanen SM.Lancet 2001; 358(3): 1500-1503\n|\n|[\u00bfSer\u00edan capaces las mujeres americanas de usas mifepristone-misprosol sin ponerse en peligro y con menos supervisi\u00f3n m\u00e9dica?(Could American women use mifepristone-misoprostol pills safely with less medical supervision?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabbb5)\nHarper C, Ellertson Ch and Winikoff BContraception 2002;65:133-142\n|\n|[La terapia continuada con infliximab es efectiva como tratamiento de la enfermedad de Crohn (Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial ). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa4c3)\nACCENT I Study Group, Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LlF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A et al.Lancet 2002;359:1541-1549\n|\n|[La galantamina para la demencia vascular: preguntas y respuestas. (Galantamine for vascular dementia: some answers, some questions) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7ab9)\nLon S SchneiderLancet 2002;359:1283-1290\n|\n|[Puesta al d\u00eda en interacciones entre productos naturales y medicamentos. (Update on natural product-drug interactions) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4a1b)\nScott GN, Gary W EAmerican Journal of Health-System Pharmacy 2002; 59(4): 339-347\n|\n|[Dosis de interfer\u00f3n beta-1b a d\u00edas alternos para la esclerosis m\u00faltiple. (Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabda0)\nDurelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M and Independent Comparison of Interferon (INCOMIN) Trial Study GroupThe Lancet, 2002; 359:1453-1460\n|\n|[Efecto protector del aceite de oliva frente al riesgo de un primer infarto de miocardio: un estudio de casos y controles en Espa\u00f1a. (Risk of first non-fatal myocardial infarction negatively associated with olive oil consumption: a case-control study in Spain) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista54cc)\nFern\u00e1ndez-Jarne E, Mart\u00ednez-Losa E, Prado-Santamar\u00eda M, Brugarolas-Brufau C, Serrano-Mart\u00ednez M, and MA Mart\u00ednez-Gonz\u00e1lezInternational Journal of Epidemiology 2002; 31: 474-480\n|\n|[Evoluci\u00f3n del consumo de antibi\u00f3ticos en Espa\u00f1a, 1985-2000 ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaae2a)\nL\u00e1zaro E, Madurga M, de Abajo MJMedicina Cl\u00ednica (Espa\u00f1a), 2002;118:561-568\n|\n|[Asma y tratamiento de la rinitis. (Intranasal steroids and the risk of emergency department visits for asthma ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9535)\nAdams RJ, Fuhbrigge AL, Filkenstein JA and Weiss STJournal of Allergy and Clinical Immunology 2002109:636-642\n|\n|[La prednisona oral incrementa la supervivencia en pacientes con mieloma m\u00faltiple. (Maintenance therpay with alternate-day prednisone improves survival in multiple myeloma patients) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5324)\nBerenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B and and Salmon ESBlood 2002;99:3163-3168\n|\n|[Suplementos de Zinc para combatir la diarrea en ni\u00f1os de los pa\u00edses en v\u00edas de desarrollo. (Effectiveness abd efficacy of zinc for the treatment of acute diarrhea in young children) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista17f9)\nStrand TA, Chadyo RK, Bahl R, Sharma PR, Adhikari RK, Bhandari N, Ulvik RJ, Mobak K, Bhan MK and Smmerfelt H.Pediatrics 2002;109:898-903\n|\n|[El tiempo de la retirada de medicamentos y advertencies de la nueva caja negra de los medicamentos de receta (Timing of new black box warnings and withdrawals for prescription Medications) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1e26)\nLasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH.JAMA 2002;287:2215-2220\n|\n|[Reducci\u00f3n de la incidencia de diabetes tipo 2 a trav\u00e9s de cambios al estilo de vida o con metformin ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac4ef)\nGrupo de Investigaci\u00f3n en la Prevenci\u00f3n de la DiabetesNew England Journal of Medicine 2002; 346(6): 393-403\n|\n|[Masajes, terapia f\u00edsica o tratamiento continuado para los pacientes con dolor cervical: un estudio aleatorio de casos y controles. (Manual therapy, physical therapy, or continued care by a general practitioner for patients with neck pain: a randomized, controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista12e1)\nHiving JLPT, Koes BW, de Vet H, van der Windt DASM, Assendelft WJJ, van Maceren H, Deville WLJM, Pool JM, Scholten RJPM, Bouter LAnnals of Internal Medicine 2002; 136 (10):713-722\n|\n|[Dolor de cuello. (Neck Pain) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7faa)\nPosner J, Glew CAnnals of Internal Medicine 2002; 136 (10):758-759\n|\n|[Las mujeres y sus hijos, \u00bfse benefician del sulfato de magnesio? Estudio de Magpie: un estudio aleatorio controlado con placebo. (Do women with pre-eclampsia, and their babies, Benefit from magnesium sulphate? The Magpie Tiral: a randomized placebo-controlled trial). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae44b)\nThe Magpie Trial Collaborative GroupThe Lancet 2002; 359(9321) 1877\n|\n|[La azitromicina y la bronquitis aguda: estudio aleatorio, controlado de doble ciego. (Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae7bd)\nEvans AT, Husain S, Durairaj L, Sadowski LA, Charles-Damte M, Wang YThe Lancet 2002; 359 (9318):1648\n|\n|[La aspirina y la prevenci\u00f3n primaria de coronariopat\u00edas. (Aspirin for primary prevention of coronary events). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae813)\nLauer MSNew England Journal of Medicine 2002; 346 (19):1468-1474\n|\n|[Modelizaci\u00f3n y predicci\u00f3n de la resistencia antimicrobina y su relaci\u00f3n con el uso de antibi\u00f3ticos. (Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3a74)\nL\u00f3pez-Lozano JM, Monnet DL, Yague A, Burgos A, Gonzalo N, Campillos P, Saez MInt. J. Antimicrob Agents 2000; 14:21-31\n|\n|[Los probi\u00f3ticos previenen la diarrea asociada a antibi\u00f3ticos: meta-an\u00e1lisis. (Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac339)\nD\u2019Souza AL, Rajkumar Ch, Cooke J, and Bulpitt ChBritish Medical Journal 2002; 324 (7350): 1361\n|\n|[Probi\u00f3ticos (Probiotics) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaef71)\nBerger ABritish Medical Journal 2002; 324 (7350): 1364\n|\n|[Tratamiento electrot\u00e9rmico intradiscal para lumbalgia discog\u00e9nica cr\u00f3nica: estudio prospectivo con dos a\u00f1os de seguimiento. (Intradiscal electrothermal treatment for Chronic Discogenic Low Back Pain: Prospective Outcome Study huir a Minimum 2-Year Follow-Up). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf1a7)\nSaal J, Saal JSpine 2002; 27 (9):966-973\n|\n|[El efecto de dosis m\u00e1s bajas de estr\u00f3genos equinos conjugados con y sin acetato de medroxiprogesterona en los huesos de mujeres con menopausia reciente. (Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early post menopausal women) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac072)\nLindsay R, Gallagher J Ch, Kleerekoper M, Picar J.JAMA 2002; 287(20): 2668-2676\n|\n|[Seguridad de los medicamentos recientemente aprobados: impacto en la prescripci\u00f3n. (Safety of newly approved drugs: implications for prescribing) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista767c)\nTemple R, Himmel HJAMA 2002; 287 (17): 2273-2275\n|\n|[Momento en que se imponen alertas en cajas negras y se retiran medicamentos de venta con receta del mercado. (Timing of new back box warnings and withdrawals for prescription medications) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2475)\nLasser K, Allen P, Woolhandler, SJ, Himmelstein D, Wolfe S, Bor DH.JAMA 2002; 287 (17): 2215-2220\n|\n|[La simvastatina reduce los niveles de prote\u00edna reactiva C en s\u00f3lo 14 d\u00edas. Un efecto independiente de la reducci\u00f3n del colesterol de lipoprote\u00edna de baja densidad (Simvastatin lowers C-reactive protein within 14 days. An effect independent of low-lensity lipoprotein cholesterol reduction) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista73a7)\nPlenge JK, Hernandez TL, BSN, Weil KM, Poirier P, Grunwald GK, Marcovina SM, Eckel RHCirculation 2002; 106:1147-1452\n|\n|[Riesgo de c\u00e1ncer entre pacientes tratados hormona del crecimiento hipofisaria entre en el Reino Unido entre 1959 y 1985: un estudio de cohorte. (Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1e4d)\nSwerdlow AJ, Higgins CD, Adlard P, Preece MAThe Lancet 2002; 360(9329):\n|\n|[Cumplimiento de terapia de estatinas entre pacientes mayores con y sin s\u00edndrome coronario agudo. (Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabfe0)\nJackevicius CA, Mamdani M, y Tu JVJournal of the American Medical Association 2002; 288(4):\n|\n|[Cumplimiento de terapia de estatinas a lo largo de los a\u00f1os entre pacientes mayores. (Long-term Persistence in Use of Statin Therapy in Elderly Patients) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista16e1)\nBenner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, y Avorn JJournal of the American Medical Association 2002; 288(4):\n|\n|[Ciprofloxacina m\u00e1s piperacilina comparada con tobramicina m\u00e1s piperacilina en pacientes con neutropenia febril.Un esnayo cl\u00ednico aleatorio a doble ciego. (Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8aa3)\nPeacock Jr JE, Herrington DA, Wade J, Lazarus HM, Reed MD, Sinclair JW, Haverstock DC, Kowalsky SF, Hurd DD, Cushing DA, Harman CP, y Donowitz GRAnnals of Internal Medicine 2002; 137(2):\n|\n|[Seguridad y eficacia de la anfotericina B liposomal comparada la anfotericina B convencional para la terapia de inducci\u00f3n de la histoplasmosis en pacientes con SIDA. (Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista680b)\nJohnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, Powderly WG, Hafner R, Kauffman CA, y WE, para el Grupo de Estudio del U.S. National Institute of Allergy and Infectious Diseases MycosesAnnals of Internal Medicine 2002; 137(2):\n|\n|[Adherencia al tratamiento de estatinas en los pacientes mayores con y sin s\u00edndromes coronorios agudos(Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae504)\nJackevicius CA, Mamdani M, Tu JVJAMA 2002; 288:462-467.\n|\n|[Persitencia en el cumplimiento de terapia de estatinas entre pacientes mayores (Long-term persistence in use of statin therapy in elderly patients) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa3c7)\nBenner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn JJAMA 2002; 288 (4):475-482\n|\n|[Los \u00e1cidos graso n-3 \u00e1cido eicosapentaenoico y \u00e1cido docosahexaenoico aumentan la distensibilidad arterial sist\u00e9mica en los humanos (The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0272)\nNestel P, Shige H, Pomeroy S, Cehun M, Abbey M y Raederstorff DAmerican Journal of Clinical Nutrition 2002;76:326-330\n|\n|[Prescripci\u00f3n inadecuada de medicamentos a personas mayores que viven en hogares. Una encuesta pobalcional (Inappropriate Drug Prescribing in home-dwelling, elderly patients. A population survey) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaad34)\nPitkala KH, Strandberg TE, Tilvis RS,Archives of Internal Medicine 2002;162:1707-1712\n|\n|[Efectos de la ingesta diaria de Vitamina E y de Multivitam\u00ednicos en infecciones agudas de v\u00edas respiratorios en personas mayores: un ensayo controlado aleatorio(Effect of daily Vitamin E and Multivitamin-Mineral Supplementation on acute respiratory tract infections in elderly persons: A randomized controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9767)\nGraat JM, Schouten EG, Kok FJJournal of the American Medical Association 2002;288:715-721\n|\n|[Comparaci\u00f3n entre heparinas de bajo peso molecular y la warfarina en la prevenci\u00f3n secundaria del tromboembolismo en pacientes con c\u00e1ncer (Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. A randomized controlled study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4d4f)\nMeyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge DArchives of Internal Medicine 2002;162:1729-1735\n|\n|[Asociaci\u00f3n entre conflicto de intereses y conclusiones: estudio aleatorio de ensayos cl\u00ednicos publicados en el BMJ (Association between competing interests and authors\u2019 conclusions: epidemiological study of randomised clinical trials published in the BMJ) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista029e)\nKjaergard LL, Als-Nielsen BBMJ 2002;325:249\n|\n|[An\u00e1lisis econ\u00f3mico de la vacuna de la gripe y tratamiento antiviral para adultos sanos. (Economic analysis of influenza vaccination and antiviral treatment for healthy working adults) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9890)\nLee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, y Peterson EDAnnals of Internal Medicine 2002;137:225-231\n|\n|[La asociaci\u00f3n de la hierba de San Juan con la elevaci\u00f3n de la hormona estimulante de la tiroides (The Association of St. John\u2019s Wort With Elevated Thyroid-Stimulating Hormona) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa800)\nHauben MPharmacotherapy 2002: 22(5) 673-675\n|\n|[Intervenciones sobre cumplimiento terap\u00e9utico: a prop\u00f3sito de un ensayo cl\u00ednico ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa7d4)\nInvestigadores del Estudio Cooperativo COM99Med Clin (Barc) 2001; 166 (Supl 2) 63-67\n|\n|[Evaluaci\u00f3n de una intervenci\u00f3n educativa para mejorar el cumplimiento del tratamiento en la hipertensi\u00f3n ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad89c)\nGrupo ADIEHTAInformatiu AATM (Agencia d\u2019Avaluaci\u00f3 de Tecnolog\u00eda i Recerca Mediques) 2002; 26: 14-15\n|\n|[Evaluaci\u00f3n del uso de medicina complementaria y alternativa en la ciudad m\u00e1s grande de la frontera M\u00e9xico-EE.UU. (Evaluation of the use of complementary and alternative medicine in the largest United Status-Mexico Border City). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista316d)\nRivera JO, Ortiz M, Lawson ME, Verma KM.Pharmacotherapy 2002; 22(2): 256-264\n|\n|[Uso de diur\u00e9ticos tiazidas y psicotr\u00f3picos, y el riesgo de fracturas de cadera en la poblaci\u00f3n mayor. Un estudio piloto (Use of thiazide diuretics, psychotropics and the risk of hip fractures in elderly people- a pilot case-control study ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2c1e)\nBraga TBT, Bergsten-Mendes G, Moreira Filho DCPharmacoepidemiology and Drug Safety, 2001; 10: S1-S164\n|\n|[Uso apropiado de antibi\u00f3ticos en un hospital universitario (Appropriateness of antibiotic use in a University Hospital) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista315a)\nFonseca RCCM, Braga BTT, Trabasso P, Bergsten-Mendes GBPharmacoepidemiology and Drug Safety 2001; 10:S1-S164\n|\n|[La tuberculosis: un problema de dificil soluci\u00f3n ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaebc7)\nThe Lancet Infectious Diseases 2002; 2: 374-6;317\n|\n|[Eficacia, seguridad y costo de los nuevos medicamentos anticancer\u00edgenos (Efficacy, safety, and cost of new anticancer drugs) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa25e)\nGarattini S, Bertele VBJM 2002; 325: 269-271\n|\n|[Riesgos y beneficios de la terapia con estr\u00f3genos y progest\u00e1genos en mujeres postmenop\u00e1usicas sanas: resultados m\u00e1s importantes del estudio aleatorio de casos y controles de la iniciativa de salud de la mujer (Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women\u2019s health initiative randomized controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista48fb)\nGrupo de investigadores de la Iniciativa de Salud de la MujerJAMA 2002; 288(3): 321-333\n|\n|[El tratamiento hormonal y el c\u00e1ncer de seno (Hormone replacement therapy in relation to breast cancer) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0a61)\nChen, ChL, Weiis NS, Newcomb P, Barlow W, White EJAMA 2002; 287(6): 734-741\n|\n|[Efectos adversos asociados con puplementos diet\u00e9ticos: un estudio observacional (Adverse events associated with dietary supplements: an observational study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa36b)\nPalmer ME, Haller C, PE McKinney, Klein-Schwartz W, Tschirgi A, Smolinske SC, Woolf A, Sprague BM, Ko R, Everson G, Nelson LS, Dodd-Butera T, Bartlett WD, Landzberg RLancet 2003; 361: 101-06\n|\n|[Anticonceptivos orales y el riesgo de infarto de miocardio (Oral contraceptives and the risk of myocardial infarction) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9647)\nTanis BC, ven den Bosch MAAJ, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, van der Graaf Y, Rosendaal FRN Engl J Med 2001; 345(25): 1787-93\n|\n|[El ABC del sistema digestivo: indigesti\u00f3n y anti-inflamatorios no esteroideos (ABC of the upper gastrointestinal tract. Indigestion and non-steroidal anti-inflamatory drugs) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9937)\nSeager JM, Hawkey CJBMJ 2001; 323: 1236-1239\n|\n|[Erradicaci\u00f3n del helicobarter pylori y riesgo de \u00falcera p\u00e9ptica en pacientes que empiezan tratamiento de largo plazo con antiinflamatorios no esteroideos: un estudio aleatorio (Eradication of helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflamatory drugs: a randomised trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaee7d)\nChan FKL, Wu JCY, Yung MY, Leung WK, Kwok T, Chan HLY, Chan CSY, Hui E, Woo J, Sung JJYThe Lancet 2002; 359: 9-13\n|\n|[Un meta-an\u00e1lisis sobre el papel del helicobacter pylori y los antiinflamatorios no esteroideos en la \u00falcera p\u00e9ptica (Role of helicobacter pylori infection and non-steroidal antiinflammatory drugs in peptic-ulcer disease: a meta-analysis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4489)\nHuang JQ, Sridhar S, Hunt RHLancet 2002; 359: 14-22\n|\n|[Profilaxis con una dosis \u00fanica de doxiciclina para la prevenci\u00f3n de la enfermedad de Lyme (borreliosis) despu\u00e9s de la picadura de Ixodes Scapularis (Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes Scapulares tick bite) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista103d)\nNadelman, RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D, Welch P, Marcus R, Ag\u00fcero-Rosenfeld ME, Dennos DT, Wormser G (en nombre del grupo de estudio de picaduras de garrapata)The New England Journal of Medicine 2201; 345(2): 79-84\n|\n|[Dos estudios controlados en pacientes sintom\u00e1ticos y con historia de enfermedad de Lyme (borreliosis) (Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7f8d)\nKlempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, Kosinski M, Weinstein AN Engl J Med 2001; 345(2): 85-92\n|\n|[Riesgo de discrasia sangu\u00ednea en una cohorte de personas que utiliza antibi\u00f3ticos (Risk of clinical blood dyscrasia in a cohort of antibiotic users) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaaecf)\nHuerta C, Garcia Rodr\u00edguez LAPharmacotherapy 2002; 22(5): 630-636\n|\n|[Peginterferon alfa-2b y ribavirin comparado con interferon alfa-2b con ribavirin para el tratamiento inicial de la hepatitis cr\u00f3nica C: un estudio cl\u00ednico aleatorio (Peginterferon alfa-2b plus ribavirin compared with interferon alfa 2-b plus ribavirin for inicial treatment of chronic hepatitis C: a randomised trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista843b)\nManns MP, McHutchison JG, Gordon ST, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling Mei-Hsiu, Albrecht JK, y el grupo internacional de intervenciones de tratamientoThe Lancet 2002; 358(9286): 958-65\n|\n|[Resultados principales del estudio ALLHAT que distribuy\u00f3 pacientes hipertensos de alto riesgo en forma aleatoria para recibir tratamiento con enzimas inhibidores de la conversi\u00f3n de la angiotensina, bloqueadores del canal del calcio o diur\u00e9tico (Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-ALLHAT) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8e6a)\nALLHAT Collaborative GroupJAMA 2002; 288(23): 2981-2997\n|\n|[Comparaci\u00f3n de los resultados del tratamiento conpravastatina vs tratamiento usual de pacientes hipertensos con hipercolesterolemia moderada. Estudio ALLHAT-LLT (Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial-ALLHAT-LLT) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista95c4)\nALLHAT Collaborative Research GroupJAMA 2002; 288(23): 2998-3007\n|\n|[Patrones de prescripci\u00f3n y necesidad de repetir el tratamiento en pacientes con otitis media (Prescribing patterns and retreatment rates in patients with otitis media) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3d83)\nShireman TI, Kelsey KAClinical Drug Investigation 2002; 22(5): 303-311\n|\n|[Tratamientos nuevos para las heridas de diab\u00e9ticos (Emerging treatmentsin diabetic wound care) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae6e6)\nDinh T, Pham H, Veves AWounds 2002; 14(1): 2-10\n|\n|[Tratamiento exitoso de las \u00falceras recalcitrantes de tal\u00f3n en diab\u00e9ticos con Becaplermin de uso t\u00f3pico (Successful treatment of recalcitrant diabetic heel ulcers with topical Becaplermin) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabeb0)\nMannari RJ, Payne WG, Ochs DE, Walusimbi M, Blue M, Robson MCWounds 2002; 14(3): 116-121\n|\n|[Resistencia a los antibi\u00f3ticos: \u00bfd\u00f3nde est\u00e1n los c\u00e9tolidos? (Antibiotic resistance: where do ketolides fit?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac9b6)\nWhite RLPharmacotherapy 2002; 22(1): 18s-29s\n|\n|[Efecto del gel de nonxynol-9 en la gonorrea urogenital y en la infecci\u00f3n por clamidia: un estudio cl\u00ednico controlado con asignaci\u00f3n aleatoria (Effect of Nonxynol-9 gel on urogenital gonorrea and chlamydial infection: A randomized controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaabea)\nRoddy R, Zekeng L, KelleyR, Tamoufe U, Tweedy KJAMA 2002; 287(9): 1117-1122\n|\n|[Utilidad de los niveles sangu\u00edneos de rifampicina en el tratamiento y seguimiento de pacientes con tuberculosis pulmonar activa que son lentos en responder a la terapia con tratamiento supervisado (Utility of rifampin blood levelsin the treatment and follow-up of active pulmonary tuberculosis in patients who were show to responde to routine directly observed therapy) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab6a2)\nMehta JB, Shantaveerapa H, Byrd R, Morton SE, Fountain F, Thomas MRChest 2001; 120(5): 1520-1524\n|\n|[Recetas inadecuadas de medicamentos para pacientes en residencias (Inappropriate medication prescribing in residencial care/assisted living facilities) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae847)\nSloane PD, Zimmerman S. Brown LC, Ives TI, Walsh JFJ. Am. Geriatr. Soc. 2002; 50:1001-1011\n|\n|[Los m\u00e9dicos de atenci\u00f3n primaria y el tratamiento con antibi\u00f3ticos de las amigdalitis en adultos. Una encuesta nacional, 1989-1999 (Antibiotic treatment of adults with sore throat by community primary care physicians. A national survey, 1989-1999) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4d9b)\nLinder JA, Stafford RSJAMA 2001; 286(10): 1181-1186\n|\n|[Los \u00df-bloqueadores en el fallo card\u00edaco. Aplicaciones cl\u00ednicas (\u00df-blockers in heart failure. Clinical Applications) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec63)\nFarell MH, Foody JM, Krumholz HMJAMA 2002; 287(7): 890-897\n|\n|[Streptococcus pneumoniae resistente a las fluoroquinolonas en Estados Unidos: 1995-1999 (Resistance of streptococcus pneumoniae to fluoroquinolones- United States, 1995-1999) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad04e)\nSin autorCDC MMWR Weekly 2001; 50(37): 800-804\n|\n|[Combatiendo la resistencia antimicrobiana: intervenciones para promover el uso adecuado de antibi\u00f3ticos (Combating antimicrobial resistance: intervention programs to promote appropriate antibiotic use) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3d4e)\nEmmer LS, Besser REInfec Med 2002; 19(4): 160-173\n|\n|[Cloranfenicol versus bencilpenicilina y gentamicina en el tratamiento de la neumon\u00eda severa en ni\u00f1os de Papua Nueva Guinea: un estudio cl\u00ednico aleatorio (Chloramphenicol versus benzylpenicillin and gentamicin for the treatment of severe pneumonia in children in Papua New Guinea: a randomised trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3104)\nDuke T, Poka H, Dale F, Michael A, Mgone J, Wal TLancet 2002; 359: 474-80\n|\n|[Mejorando la informaci\u00f3n sobre reacciones adversas en pacientes ambulatorios en un hospital de excombatientes (Improving adverse-drug-reaction reporting in ambulatory care clinics at a veterans affairs hospital) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1a97)\nEspinall MB, Whittle J, Aspinall SL, Maher RL, Good CBAm J Health-Syst Pharm 2002; 59 (9): 841-845\n|\n|[Acetaminof\u00e9n, aspirina y fallo renal cr\u00f3nico (Acetaminophen, aspirin, and chronic renal failure) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista79f0)\nFored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, Lipworth L, Elinder CG, Blot WJ, MacLaughlin JK, Zack MM, Nyr\u00e9n ON Engl J Med 2001; 345 (25): 1801-1808\n|\n|[Inhibidores de la ciclo-oxigenasa y los efectos antiplaquetarios de la aspirina (Cyclooxygenase inhibitors and the antiplatelet effects of aspirin) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8fa5)\nCatella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, Fitzgerald GAN Engl J Med 2001; 345(25): 1809-1817\n|\n|[Implicaciones cl\u00ednicas de las interacciones de medicamentos con los coxibs (Clinical implications of drug interactions with coxibs) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista83d4)\nGarnett WRPharmacotherapy 2001; 21(10): 1223-1232\n|\n|[Seguimiento del tratamiento por la poblaci\u00f3n inmigrante: vietnamitas americanos (Medication adherence in an immigrant population: Vietnamese Americans) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad06e)\nNguyen N, Achusim ELDrug Benefit Trends 2002; 14(4): 34-35, 39-48\n|\n|[El tratamiento del acn\u00e9 en adolescentes: un acercamiento gradual a su tratamiento (Adolescent Acne: a stepwise approach to management) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista74d4)\nWoodard ITopics in Advanced Nursing Journal 2002; 2(2)\n|\n|[La risperidona y el haloperidol en la prevenci\u00f3n de recidivas en pacientes con esquizofrenia (A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7a13)\nCsernansky JG, Brenner RN Engl J Med 2002; 346(1): 16-22\n|\n|[Naltrexone en el tratamiento de la dependencia alcoh\u00f3lica (Naltrexone in the treatment of alcohol dependence) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa543)\nCristal JH, Cramer JA, Krol WF, Kira GF, Rosenheck RAN Engl J Med 2001; 345(24): 1734-9\n|\n|[Comprensi\u00f3n y tratamiento de la migra\u00f1a (Migraine- current understanding and treatment. ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1ea4)\nGoadsby PJ, Lipton RB, Ferrari MDN Engl J Med 2002; 346(4): 257-270\n|\n|[Eficacia de la vacuna contra la malaria por plasmodium falciparum RTS,S/ASO2 en poblaci\u00f3n adulta semi-inmune de Gambia: un estudio aleatorio (Efficacy of RTS,S/ASO2 malaria vaccine against plasmodium falciparum infection in semi-immune adult men in Gambia: a randomised trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9094)\nBojang AK, Milligan PJM, Pinder M, Vigneron L, Alloueche A, Kester KE, Ripley Ballou W, Conway DJ, Reece WHH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KPWJ, Tornieporth N, Cohen JD, Doherty TThe Lancet 2001; 358: 1927-34\n|\n|[Comparaci\u00f3n del tratamiento del p\u00e9nfigo ampolloso con corticosterides por v\u00eda oral o por v\u00eda t\u00f3pica (A comparison of oral and topical costicosteroids in patients with bullous pemphigoid) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1fc5)\nJoly P, Roujeau JC, Benichou J, Richard C, Dreno B, Delaporte E, Vaillant L, D\u2019Incan M, Plantin P, Bedane C, Young P, Bernard PN Engl J Med 2002; 346 (5): 321-7\n|\n|[Inhibidores directos de la trombina en el s\u00edndrome coronario agudo: resultados principales de un meta-an\u00e1lisis basado en datos individuales (Direct thrombin inhibitors in acute coronary s\u00edndromes: principal results of a meta-analysis base don individual patients\u2019 data) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistacffd)\nGrupo colaborativo para el estudio de los inhibidores directos de la trombinaLancet 2002; 359: 294-302\n|\n|[Tratamiento masivo para eliminar la filariasis en Papua Nueva Guinea (Mass treatment to eliminate filariasis in Papua New Guinea) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista049c)\nBockarie MJ, Tisch DJ, Kastens W, Alexander NDE, Dimber Z, Bockarie F, Ibam E, Alpers MP, Kazura JWNew England Journal of Medicine 2002; 347:1841-1848\n|\n|[Efectos de nitazoxanida en la morbilidad y mortalidad en ni\u00f1os de Zambia con criptosporidiosis: un ensayo cl\u00ednico aleatorio controlado (Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista17a6)\nAmadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, Kelly PLancet 2002; 360: 1375-80\n|\n|[Comparaci\u00f3n de una dosis \u00fanica de azitromicina y 12 dosis durante tres d\u00edas de eritromicina para ni\u00f1os con c\u00f3lera: ensayo doble ciego aleatorio (Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae9b3)\nKhan WA, Saha D, Rahman A, Salam MA, Bogaerts J, Bennish MLLancet 2002; 360:1722-1727\n|\n|[Tratamiento del resfriado com\u00fan con equinacea no refinada (Treatment of the common cold with unrefined Echinacea. A randomized, double-blind, placebo-controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8b6f)\nBarrett BP, Brown RL, Locken K, Maberry R, Bobula JA, D\u2019Alessio DAnnals of Internal Medicine 2002; 137(12): 939-946\n|\n|[ \u00bfTiene la declaraci\u00f3n de conflicto de intereses alg\u00fan impacto en los lectores? Un estudio aleatorio de lectores (Does declaration of competing interests affect readers\u2019 perceptions? A randomised trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6668)\nChaudhry S, Schroter S, Smith R, Morris JBMJ 2002; 325:1391-1392\n|\n|[Plantas medicinales: la necesidad de nuevas regulaciones (Botanical medicines. The need for new regulations) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista71c4)\nMarcus DM, Grollman APNew England Journal of Medicine 2002; 347(25)\n|\n|[Tratamiento solamente con sulfadoxina y pirimetamina o con amodiaquina o artesunato para el tratamiento de la malaria sin complicaciones: ensayo aleatorio longitudinal (Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal ramdomised trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6a4b)\nDorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, Staedke SG, Gasasira A, Rosenthal PJLancet 2002; 360: 2031-38\n|\n|[Terapia de estr\u00f3genos para prevenir el reinfarto en mujeres postmenop\u00e1usicas: ensayo controlado aleatorio (Estrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5479)\nThe ESPRIT teamThe Lancet, 2002; 360; 9350\n|\n|[Terapia ambulatoria para tuberculosis multiresistente en Lima, Per\u00fa (Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista50dc)\nMitnick C, Bayona J, Palacios E, Shin S, Furin J, Alc\u00e1ntara F, S\u00e1nchez E, Sarria M, Becerra M, Smith Fawzi MC, Kapiga S, Neuberg D, Maguire JH, Yong Kim J, Farmer PNew England Journal of Medicine 2003; 348:119-128\n|\n|[Decisiones reguladoras en un mundo globalizado: el efecto domin\u00f3 de la retirada de la fenilpropamina en Am\u00e9rica Latina (Regulatory decisions un a globalised world: the domino effect of phenylpropanolamine withdrawal in Latin America) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad39c)\nFigueras A, Laporte JDrug Safety 2002; 25(1): 689-93\n|\n|[Uso de antisic\u00f3ticos en Espa\u00f1a 1985-2000 (Use of antipsychotic agents in Spain through 1985-2000) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7e92)\nSantamar\u00eda B, P\u00e9rez M, Montero D, Madurga M, de Abajo FJEuropean Psychiatry 2002; 17(8): 471-6\n|\n|[Medicamentos y el mundo en desarrollo (Pharmaceuticals and the developing world) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2a78)\nKremer MJournal of Economic Perspectives 2002; 16 (4): 67-90\n|\n|[La administraci\u00f3n r\u00e1pida de antibi\u00f3ticos bien seleccionados reduce la estad\u00eda hospitalaria de pacientes con neumon\u00eda adquirida fuera del hospital: v\u00ednculos entre la calidad de atenci\u00f3n y la utilizaci\u00f3n de los recursos (Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista71fe)\nBattleman DS, Callahan M, Thaler HTArchives of Internal Medicine 2002; 162(6): 682-688\n|\n|[Factores de riesgo comunes de las colonizaciones e infecciones nosocomiales por estafilococo dorado resistente, enterococo, bacilos gram negativos, clostridium difficile, y c\u00e1ndida (The commonlaity of risk factors for nosocomial colonization and infection with antimicrobial-resistant staphylococcus aureus, enterococcus, gram-negative bacilli, clostridium difficile, y candida) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7b9d)\nSafdar N, Maki DGAnnals of Internal Medicine 2002; 136: 834-844\n|\n|[Fluoroquinolonas y problemas del tend\u00f3n de Aquiles: un estudio de casos y controles (Fluoroquinolones and risk of Achilles tendon disorders: case-control study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad037)\nVan der Linden PD, Sturkenboom MCJM, Herings RMC, Leufkens HGM, Sticker BHChBMJ 2002; 324: 1306-7\n|\n|[Recetas de medicamentos que no est\u00e1n aprobados para uso infantil: un estudio de comunidad (Unlicensed and off label prescription of drugs to children: population based cohort study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7f62)\nJong GW, Alend IA, Sturkenboom MCJM, van den Ander JN, Stricker BHChBMJ 2002; 324: 1313-1314\n|\n|[Prescripci\u00f3n de medicamentos para usos no aprobados en ni\u00f1os, en servicios de atenci\u00f3n primaria de Alemania: estudio retrospectivo de cohorte (Off label prescribing to children in primary care in Germany: retrospective cohort study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista80c5)\nBucheler R, Schwab M, Morike K, Kalchthaler B, Mohr H, Schroder H, Schwoerer P, Gleiter CHBMJ 2002; 324: 1311-1312\n|\n|[Utilizaci\u00f3n de medicamentos para usos no aprobados en pediatr\u00eda. Estudio trasversal a nivel de comunidad (Unlicensed and offlabel drug use by children in community: cross sectional study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista659b)\nSchirm E, tobi H, Lolkje TW de Jong-van den BergBMJ 2002; 324: 1312-1313\n|\n|[Ensayo cl\u00ednico del tratamiento de la hepatitis B cr\u00f3nica en ni\u00f1os con lamivudin (Clinical trial of lamivudine in children with chronic hepatitis B) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafcf0)\nJonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell SM, Sokal EMNEJM 2002; 346: 1706-1713\n|\n|[La participaci\u00f3n del farmac\u00e9utico en la visita hospitalaria reduce los errores en la medicaci\u00f3n ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistada17)\nScarsi KK, Fotis MA, Noskin GAAm J Health-Syst Pharm 2002; 59(21): 2089-2092\n|\n|[Impacto cl\u00ednico y econ\u00f3mico de las recomendaciones farmac\u00e9uticas en un centro m\u00e9dico para excombatientes ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3843)\nLee AJ, Boro MS, Knapp KK, Meier JL, Korman NEAm J Health-Syst Pharm 2002; 59(21): 2070-2077\n|\n|[La fibrilaci\u00f3n auricular requiere que se trate mejor con warfarina ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista86c7)\nScott PStroke 2002; 33: 2664-2669\n|\n|[La percepci\u00f3n de los pacientes de la adhesi\u00f3n al tratamiento no es real ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6ac5)\nBuelow JJournal of Neuroscience Nursing 2001; 33:260-269\n|\n|[Impacto de la Terapia Observada (DOTS) con DOTS-plus en la tuberculosis multidrogo resistente y en las muertes por tuberculosis: an\u00e1lisis de decisi\u00f3n. (Impact of DOTS compared with DOTS-plus on mutidrug resistant tuberculosis and tuberculosis deaths: decision analysis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista41c7)\nSterling TR, Lehmann HP, Frieden TRBritish Medical Journal, 2003; 326: 574-579\n|\n|[Medicinas, Sociedad e Industria (Medicines, Society, and Industry) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8d96)\nAstrid JThe Lancet, 2002; 360: 9343\n|\n|[La industria farmac\u00e9utica como informante. (The pharmaceutical industry as an informant) Collier J ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista607b)\nThe Lancet, 2002; 360: 1405-9\n|\n|[La industria farmac\u00e9utica como influencia pol\u00edtica. (The pharmaceutical industry as a political player) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2731)\nAbraham JThe Lancet, 2002: 360: 1498-502\n|\n|[La industria farmac\u00e9utica como proveedora de medicamentos. (The pharamceutical industry as a medicines provider) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2924)\nHenry D, Lexchin JThe Lancet, 2002; 360: 1590-95\n|\n|[A qui\u00e9n responde la industria. (Accountability of the pharmcaceutical industry) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab6dd)\nDukes MNGThe Lancet, 360: 1682-84.\n|\n|[Tratamiento masivo para eliminar la filiariasis en Papua Nueva Guinea. (Mass treatment to eliminate filiariasis in Papua New Guinea) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab21c)\nFrighi VThe New England Journal of Medicine, 2002; 347: 1841-1848\n|\n|[Miltefosina oral para el tratamiento de la leishmaniasis visceral de la India. (Oral miltefosine por Indian visceal leishmaniasis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6943)\nSundar S et al.The New England Journal of Medicine, 2002; 347: 1739-1746\n|\n|[Tratamiento en la comunidad para la tuberculosis multidrogo resistente en Lima, Per\u00fa. (Community-based Therapy for Multidrug-Resistant Tuberculosis in Lima, Per\u00fa)v ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5ca3)\nMitneck et alThe New England Journal of Medicine, 2003; 348:119-128\n|\n|[Los efectos anticompetitivos de los seudo-gen\u00e9ricos en el mercado farmac\u00e9utico canadiense. (The anti-competitive effects of brand-controlled \u201cpseudo-generics\u201d in the Canadian pharmeceutical market) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistada40)\nHollis ACanadian Public Policy 2003; 39 (1) 21-32\n|\n|[An\u00e1lisis coste-efectividad del empleo de celecoxib en el tratamiento de artrosis ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaeaa2)\nMoreno A et al.Gaceta Sanitaria 2003; 17(1): 27-36\n|\n|[Derrumbando el efecto placebo y encontrando el significado de la respuesta. (Deconstructing the placebo effect and finding the meaning response) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistacb0f)\nMoerman DE, Jonas WBAnnals of internal Medicine 2002; 136: 471-6\n|\n|[Evaluando los tratamientos medicamentosos para el Parkinson: \u00bfson buenos los ensayos cl\u00ednicos?. (Evaluating drug treatments for Parkinson\u2019s disease: how good are the trials?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabc09)\nWhetaley K, Store RL, Clarke CE, Hills RK, Williams AC, Gray RBritish Medical Journal 2002; 324:1508-11\n|\n|[\u00bfHasta d\u00f3nde se ha vendido la medicina? (Just how tainted has medicine become?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabc23)\nAn\u00f3nimoThe Lancet 2002; 359: 1167\n|\n|[Calidad de las farmacias globales del internet: \u00bfpodemos proteger a los consumidores? (Quality of global e-pharmacies: can we safeguard consumers?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3fed)\nBessell TL et al.European Journal Clinical Pharmacology 2002; 58:567-571\n|\n|[H\u00e1bitos de prescripci\u00f3n de los m\u00e9dicos que venden medicamentos y la de los que no lo hacen en Zimbabwe (Prescription habits of dispensing and non-dispensing doctors in Zimbabwe) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista865a)\nTrap B et al.Health Policy and Planning 2002; 17(3): 288-295\n|\n|[Influencia de la evidencia nueva en los patrones de prescripci\u00f3n. (Influence of new evidence on prescription patterns) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3091)\nCalvo CB, Rubinstein AJournal of the American Board of Family Practice 2003; 15 (6): 457-462\n|\n|[Exacerbaci\u00f3n del asma asociada a los suplementos de condroitina y glucosamina (Asthma exacerbation associated with glucosamine-chondroitin supplement) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista24c3)\nTallia AF, Cardone AJournal of the American Board of Family Practice 2003; 15 (6): 481-484\n|\n|[Los pediatras que recetan Lotrisone los suelen utilizar en zonas inadecuadas aunque sepan su potencia. (Pediatricians qho prescribe clotrimazole-betamethasone dipropionate, Lotrisone, often utilize it in inappropriate settings regardless of their knowlege of the Drug\u2019s Potency). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9583)\nRailan D, Wilson JK, Feldman ST, Fleischer ABDermatology Online Journal 2002; 8(2)\n|\n|[Sugerencias para el entrenamiento de t\u00e9cnicos de farmacia: los cambios ya no pueden esperar. (White paper on pharmacy technicians 2002: needed changes can no longer wait) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaeea6)\nSin autorAmerican Journal of Health Systems Pharmacy 2002; 60 (1): 37-51\n|\n|[Discrepancia entre la norma y la pr\u00e1ctica en el uso de quimioterapia coadyuvante en las mujeres con c\u00e1ncer de mama.(Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac3ab)\nDu Lx, et al.Annals of Internal Medicine 2003; 138: 90-97\n|\n|[Los inhibidores de la reabsorci\u00f3n de la serotonina y el riesgo de sangrado gastrointestinal: un estudio de cohorte (Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: A population-based cohort study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad88d)\nDalton SO, Johansen Ch, Mellemkjaer L, Sorensen H, Norgard B, Olsen, JArchives of Internal Medicine 2003; 163:59-64\n|\n|[Las patentes y los medicamentos: un estudio reciente dice que el derecho a la salud debe prevalecer (Patents and medicines: The relationship between TRIPS and the human right to health) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabe83)\nPhilippe Cullet, IELRC www.ielrc.orgInternacional Affairs 2003: 79(1): 139-160\n|\n|[Las dosis de los medicamentos nuevos son con frecuencia demasiado altas (New drug\u2019s dosages often too high) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafbdf)\nStephenson JJAMA 2002; 288 (13):1578\n|\n|[Un acuerdo entre el sector p\u00fablico y el privado para el control de la malaria: lecciones del programa de donaci\u00f3n de Malarone (A public-private partnership for malaria control: lessons from the Malarone Donation Programme) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistadb07)\nOlukayode Oyediran ABO, Ddumba EM, Ochola SA, Lucas AO, Koporc K, Dowdle WRBulletin of the World Health Organization 2002; 80:817-821\n|\n|[Ensayo cl\u00ednico aleatorio de aspirina para prevenir adenomas colorrectales en pacientes con historia de cancer colorrectal (A Randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6db1)\nSandler RS et al.New England Journal of Medicine 2003; 348(10): 883-890\n|\n|[Precisi\u00f3n de los anuncios en las revistas m\u00e9dicas (Accuracy of pharmaceutical advertisements in medical journals) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9473)\nVillanueva P, et al.\nThe Lancet 2003; 361: 9351\n[ http://www.thelancet.com/journal/vol361/iss9351/full/llan.361.9351.original%20_research.23828.1](http://www.thelancet.com/journal/vol361/iss9351/full/llan.361.9351.original%20_research.23828.1)\n|\n|[La terapia de interferon despu\u00e9s de la ablaci\u00f3n del tumor mejora la prognosis en pacientes con carcinoma hepatocelular asociado con el virus de hepatitis C (Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with Hepatitis C virus) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista217a)\nShiratori Y et alAnnals of Internal Medicine 2003; 138(4): 299-306\n|\n|[Eficacia de suplemento vitamina oral D3 (cholecalciferol)cada cuatro meses en fracturas y mortalidad en hombres y mujeresque que no est\u00e1n internados:ensayo cl\u00ednico aleatorio a doble ciego. (Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaeb5a)\nTrivedi DP et alBMJ 2003; 326: 469-475\n|\n|[Uso de plantas medicinales entre embarazadas (Herbal medicine use in parturients) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista17c2)\nHepner DL et al dhepner@partners.orgAnesthesia and Analgesia, 2002; 94:690-693\n|\n|[Eventos cerebrovasculares y cardiovasculares en pacientes tratados por la infecci\u00f3n VIH (Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1cea)\nBozzette SA et al.New England Journal of Medicine 2003; 348(8):702-710\n|\n|[Servicios m\u00e9dicos de internado y ensayos cl\u00ednicos de c\u00e1ncer en fase I (Hospice benefits and phase I cancer trials) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac61e)\nByock I, Miles SHAnn Intern Med 2003; 138:335\u2013337\n|\n|[Retenci\u00f3n al cabo de un a\u00f1o y funci\u00f3n social despu\u00e9s de tratamiento con buprenorfina para prevenir la reca\u00edda en la dependencia a la hero\u00edna: ensayo cl\u00ednico aleatorio con placebo (1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2fec)\nKakko J et alThe Lancet 361, 9358:662-668\n|\n|[Prevenci\u00f3n de la recidiva en trastornos depresivos tratados con medicamentos antidepresivo: una revisi\u00f3n sistem\u00e1tica de la literatura (Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac5c8)\nGeddes JR et alLancet 2003; 361: 653-51\n|\n|[\u00bfSon los grandes ensayos cl\u00ednicos de enfermedades mortales a corto plazo generalmente poco \u00e9ticos? (Are large clinical trials in rapidly lethal diseases usually unethical?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae470)\nHorrobin DFLancet 2003; 361: 695-97\n|\n|[Apolipoprote\u00ednas versus l\u00edpidos como indices de riesgo coronario y como objetivos de tratamiento con estatinas (Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0b66)\nSniderman AD, et alLancet 2003; 361: 777-80\n|\n|[Relaci\u00f3n entre la terapia hormonal sustitutiva y enfermedad insqu\u00e9mica del coraz\u00f3n en mujeres: estudio de observaci\u00f3n prospectivo (Relation between hormone replacement therapy and ischaemic heart disease in women: prospective observational study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6218)\nL\u00f8kkegaard E et alBritish Medical Journal 2002; 326 (7386):426-431\n|\n|[Adici\u00f3n de la ifosfamida y el etop\u00f3sido a la pauta est\u00e1ndar de quimoterapia de sarcoma de Ewing y de tumor \u00f3seo neuroectod\u00e9rmico primitivo (Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor ofbBone) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista417d)\nGrier E et.The New England Journal of Medicine 2003; 348(8):694-701\n|\n|[Est\u00e1ndares de legibilidad y legibilidad real de las formas de consentimiento informado Readability (Standards for Informed-Consent Forms as Compared with Actual Readability) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabab3)\nPaasche-Orlow MK et alNew England Journal of Medicine 2003; 348(8): 721-726\n|\n|[Una comparaci\u00f3n de los resultados de los inhibidores de ECA con diur\u00e9ticos para el tratamiento de la hipertensi\u00f3n en ancianos (A Comparison of outcomes with angiotensin-converting\u2013enzyme inhibitors and diuretics for hypertension in the elderly) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2b09)\nWing LMH et al, para el Second Australian National Blood Pressure Study GroupNew Eng J of Med 2003; 348(7): 583-592\n|\n|[Una comparaci\u00f3n entre el sulfato de magnesio y el nimopidio en la prevenci\u00f3n de eclampsia (A Comparison of magnesium sulfate and nimodipine for the prevention of eclampsia) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabe47)\nBelfort MA et al. para el Grupo de Estudio de NimodipinoNew Eng J of Med 2003; 348(4): 304-311\n|\n|[Efectividad de intervenciones educativas basadas en el contacto personal para mejorar la calidad de la prescripci\u00f3n en atenci\u00f3n primaria: un ensayo cl\u00ednico aleatorio controlado y pragm\u00e1tico (One-to-one versus groupsSessions to improve prescription in primary care: A pragmatic randomized controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac36b)\nFigueiras A et al.Medical Care 2001; 39:158-167\n|\n|[Uso de inhibidores de inhibidores selectivos de recaptaci\u00f3n de serotina y riesgo de hemorragia digestiva : Un estudio poblacional de cohortes (Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: A population-based cohort Study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistacbc4)\nDalton SO et al.Arch Intern Med. 2003; 163: 59-64\n|\n|[Ensayo cl\u00ednico prospectivo y aleatorio de suplementos antioxidantes en pacientes operados enfermos cr\u00edticos (Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6faa)\nNathens AB, et al.Annals of Surgery 2003; 236:814-822\n|\n|[Los enfermeros pueden reportar reacciones adversas (Reporting of adverse drug reactions by nurses) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistadf6c)\nMorrison-Griffiths S, et al\nLancet 2003; 361: 1347\u201348\n[ http://www.thelancet.com/journal/vol361/iss9366/full/llan.361.9366.original_research.25317.1](http://www.thelancet.com/journal/vol361/iss9366/full/llan.361.9366.original_research.25317.1)\n|\n|[La nueva generaci\u00f3n de antisic\u00f3ticos versus antisic\u00f3ticos convencionales de baja potencia: una revisi\u00f3n sistem\u00e1tica y un meta-an\u00e1lisis (New Generation antipsychotics versus low potency conventional antipsychotics: a systematic review and meta-analysis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaee94)\nLeucht S, Wahlbeck K, Harmann J, Kissling WLancet 2003; 361: 1581-89\n|\n|[Gen\u00e9ricos: \u00bfbuenos o malos? Conocimientos y actitudes de los m\u00e9dicos ante los medicamentos gen\u00e9ricos ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista833c)\nGarc\u00eda AJ, Martos F, Leiva F, S\u00e1nchez de la Cuesta FGaceta Sanitaria 2003; 17: 144 \u2013 149\n|\n|[Incidencia y prevenci\u00f3n de eventos medicamentos adversos entre personas mayores en tratamiento extrahospitalario (Incidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory Setting) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista08a4)\nGurwitz JH et alJAMA 2003; 289:1107-1116\n|\n|[Un m\u00e9todo para evaluar la informaci\u00f3n que presentan los prospectos para pacientes (A method to evaluate patient information leaflets publications) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae8d4)\nGustafsson J et al.Drug Information Journal 2003; 37: 115-125\n|\n|[Eventos medicamentosos adversos en atenci\u00f3n primaria (Adverse Drug Events in Ambulatory Care) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabfc9)\nGandhi K et al.N Engl J Med 2003; 348:1556-64\n[ http://content.nejm.org/cgi/content/short/348/16/1556](http://content.nejm.org/cgi/content/short/348/16/1556)\n|\n|[Efecto de un suplemento multivitam\u00ednico y de minerales sobre las infecciones y la calidad de vida. Un ensayo randomizado, doble ciego y controlado con placebo ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9104)\nBarringer TA et al.Annals of Internal Medicine 2003; 138:365-371\n|\n|[Uso de medicamentos en el tratamiento de insomnia en ni\u00f1os (Medication Use in the Treatment of Pediatric Insomnia: Results of a Survey of Community-Based Pediatricians) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac1f2)\nOwens JA et al.Pediatrics 2003; 111:e628-e635\n|\n|[Medicamentos en las noticias: un an\u00e1lisis de los peri\u00f3dicos canadienses y la informaci\u00f3n que presentan sobre medicamentos de receta (Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8bc3)\nCassels A, et al.Canadian Medical Association Journal 2003;168 1133-1137\n[http://www.cmaj.ca/cgi/content/abstract/168/9/1133](http://www.cmaj.ca/cgi/content/abstract/168/9/1133) o\n[ www.policyalternatives.ca](http://www.policyalternatives.ca/)\n|\n|[Un ensayo cl\u00ednico aleatorio de aspirina para prevenir adenomas colorrectales (A randomized trial of aspirin to prevent colorectal adenomas) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2d4a)\nBaron JA et alNew England Journal of Medicine 2003; 348(10): 891-899\n|\n|[Medicaci\u00f3n del sistema nervioso central y el riego de fractura en mujeres mayores (Central Nervous System Active Medications and Risk for Fractures in Older Women) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7ad8)\nEnsrud KE et al para el Estudio del Grupo de Investigaci\u00f3n de Fracturas Osteopor\u00f3tico (Study of Osteoporotic Fractures Research Group)Archives of Internal Medicine 2003; 163-949-957\n|\n|[Asociaci\u00f3n entre la prescripci\u00f3n de antidepresivos y suicidios en Australia, 1991-2000: un an\u00e1lisis de tendencias (Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend an\u00e1lisis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistadc2f)\nHall WD, Mant A, et alBritish Medical Journal 2003; 326:1008-1011\n|\n|[El impacto de la retinitis por citomegalovirus en la calidad de vida de los pacientes de VIH/Sida en terapia antirretorvial (The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa102)\nKempen JH et al. Studies of Ocular Complications of AIDS Research GroupOphthalmology 2003; 110: 987-995\n|\n|[Predictores de la prescripci\u00f3n de antibi\u00f3ticos de amplio espectro para infecciones agudas del tracto respiratorio del adulto en atenci\u00f3n primaria (Predictors of Broad-Spectrum Antibiotic Prescribing for Acute Respiratory Tract Infections in Adult Primary Care) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf7cb)\nSteinman MA et alJAMA 2003;289:719-72\n|\n|[Eficacia y costo efectividad de tratamiento psicol\u00f3gico y con medicamentos de pacientes con problemas mentales comunes en atenci\u00f3n general en Goa, India. Un estudio aleatorio controlado (Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India; a randomised, controlled trial). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4e07)\nVikram Patel, Daniel Chisholm, Sophia Rabe-Hesketh, Fiona Dias-Saxena, Gracy Andrew, Anthony MannThe Lancet 2003; 361:9351\n|\n|[Precisi\u00f3n de los anuncios sobre medicamentos en las revistas m\u00e9dicas. (Accuracy of pharmaceutical advertisements in medical journals) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4352)\nPilar Villanueva, Salvador Peir\u00f3, Juli\u00e1n Librero, Inmaculada Pereir\u00f3The Lancet 2003; 361:9351\n|\n|[Una alternativa escondida: obteniendo los tratamientos que est\u00e1n siendo investigados sin participar en el estudio (The hidden alternativs: getting investigational treatments off-study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae81c)\nJerry MenikoffThe Lancet 2003; 361: 9351\n|\n|[El resfriado com\u00fan (The common cold) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaedaf)\nTerho Heikkinen, Asko J\u00e4rvinenThe Lancet 2003; 361: 9351\n|\n|[Necrolisis epid\u00e9rmica t\u00f3xica a consecuencia de la administraci\u00f3n de Celecoxib (Celebrex) (Toxic epidermal necrolysis due to administration of celecoxib-Celebrex) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabb1b)\nBruce Friedman, MD, Hermann K. Orlet, MD, Joseph M. Still, MD, Edward Law, MDSouth Med J 95(10):1213-1214, 2002.\n|\n|[Los pediatras cuando recetan antibi\u00f3ticos para infecciones respiratorias agudas, \u00bfsiquen los principios adecuados? (Are pediatricians adhering to principles of judicious antibiotic use for upper respiratory tract infections? ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaeb98)\nSumathi Nambiar, MD, Richard H. Schwartz, MD, Michael J. Sheridan, ScDSouth Med J 95(10):1163-1167, 2002.\n|\n|[Resistencia antimicrobiana a la Escherichia coli o26, 0103, 0111, 0128, y 0145. DE los animales a los humanos. (Antimicrobial Resistance of Escherichia coli O26, O103, O111, O128, and O145 From Animals and Humans) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac467)\nCarl M. Schroeder, Jianghong Meng, Shaohua Zhao, Chitrita DebRoy, Jocelyn Torcolini, Cuiwei Zhao, Patrick F. McDermott, David D. Wagner, Robert D. Walker, David G. WhiteEmerg Infect Dis 2002; 8(12), 2002\n|\n|[El risedronato previene nuevas fracturas vertebrales en mujeres postmenopausicas de alto riego (Risedronate prevents new bertebral fractures in postmenopausal women at high risk) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaed2b)\nWatts NB, et al nelson.watts@uc.edu.The Journal of Clinical Endocrinology & Metabolism 2003; 88(2): 542-549\n|\n|[Asociaci\u00f3n entre la concentraci\u00f3n de digoxina en la sangre y la supervivencia de pacientes con insuficiencia cardiaca (Association of serum digoxin concentration and outcomes in patients with heart failure) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista318c)\nRathore SS et alJAMA, 2003; 289:871-878\n|\n|[El uso de estatinas, las fracturas y la densidad \u00f3sea en mujeres postmenopa\u00fasicas: resultados del estudio observacional de la iniciativa de salud de la mujer (Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women\u2019s Health Initiative Observational Study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafe82)\nLaCroix, AZ et al.Ann Intern Med. 2003;139:97\u2013104\n|\n|[Los anti-inflamatorios no esteroideos y la enfermedad de Alzheimer: revisi\u00f3n sistem\u00e1tica y meta-an\u00e1lisis de estudios observacionales. (Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer\u2019s disease: systematic review and meta-analysis of observational studies) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5b93)\nEtminan M, et al.BMJ 2003;327:128\n|\n|[Una forma interesante de obtener el consentimiento para hacer investigaci\u00f3n de pacientes terminales que no est\u00e1n en condiciones de dar su consentimiento. (Novel consent process for research in dying patients unable to give consent) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3b0a)\nRees E y Hardy JBMJ 2003;327:198\n|\n|[Tratamiento con acarbosa y el riesgo de enfermedad cardiovascular e hipertensi\u00f3n en pacientes con problemas de tolerancia a la glucosa: The STOP-NIDDM Trial (Acarbose reatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabddd)\nChiasson JL el al.JAMA. 2003;290:486-494\n|\n|[Incidencia de c\u00e1ncer y mortalidad despu\u00e9s de administrar suplementos de tocoferol y carotenos. Un estudio post-intervenci\u00f3n(Incidence of cancer and mortality following -tocopherol and -carotene supplementation. A postintervention follow-up) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad258)\nThe ATBC Study GroupJAMA. 2003;290:476-485.\n|\n|[Primero dieta, luego medicaci\u00f3n para la hipercolesterolemia. (Diet first, then medication for hipercolesterolemia) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6be6)\nAnderson JWJAMA 2003; 290: 531-533.\n|\n|[El manejo de la influenza en adultos mayores de 65 a\u00f1os: la costo-efectividad de los test r\u00e1pidos y de la terapia antiviral (Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8b0a)\nRothberg MB. et al.Ann Intern Med. 2003; 139: 321-329\n|\n|[El tenofovir disoproxil fumarato en infectados por VIH-1 resistente a los nucle\u00f3sidos. (Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection . A randomized trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1d23)\nSquires K et al.Ann Intern Med. 2003; 139: 313-320\n|\n|[La importancia de la preferencia de los pacientes en las decisiones terap\u00e9uticas- un reto para los m\u00e9dicos. (The importance of patient preferences in treatment decisions\u2014challenges for doctors) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista661f)\nSay RE y Thomson RBMJ 2003; 327:542-545\n|\n|[El impacto de la consulta con los departamentos de \u00e9tica en el mantenimiento de tratamientos in\u00fatiles en las unidades de cuidados intensivos. (Effect of ethics consultations on nonbeneficial life-sustaining treatments in the intensive care setting) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8de6)\nSchneiderman LJ, et al.JAMA. 2003; 290:1166-1172\n|\n|[Impacto del entrenamiento en comunicaci\u00f3n en el desempe\u00f1o de los estudiantes de medicina. (Effect of communications training on medical student performance) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7e0d)\nYedidia MJ et al.JAMA 2003; 290:1157-1165\n|\n|[Cuidados en la casa (Home care) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista049c-2)\nLevine SA. et al.JAMA.2003; 290: 1203-1207\n|\n|[Ximelagatran por v\u00eda oral para la profilaxis secundaria del infarto de miocardio: el estudio cl\u00ednico aleatorio ESTEEM (Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae888)\nWallentin L et al. Para el grupo ESTEEMLancet 2003; 362: 789-97\n|\n|[La eficacia del perindopril en reducir los problemas cardiovasculares entre pacientes con patolog\u00eda coronaria estable: estudio multic\u00e9ntrico, aleatorizado, de doble ciego, controlado con placebo. (Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1d83)\nThe European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigatorsLancet 2003; 362: 782-88\n|\n|[El efecto del candesartan en pacientes con insuficiencia cardiaca cr\u00f3nica y reducci\u00f3n de la funci\u00f3n sist\u00f3lica del ventr\u00edculo izquierdo con intolerancia a los enzima inhibidores de la angiotensina: estudio cl\u00ednico CHARM) (Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaea4a)\nGranger CB et al. para los comit\u00e9s e investigadores CHARMLancet 2003; 362: 772-776\n|\n|[Efecto del candesartan en pacientes con insuficiencia cardiaca cr\u00f3nica en pacientes en tratamiento con IECAs : studio cl\u00ednico CHARM (Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4b61)\nMcMurray JJV et al. para los comit\u00e9s e investigadores CHARMLancet 2003; 362: 767-71\n|\n|[Efecto del candesartan en la morbilidad y mortalidad de pacientes con insuficiencia cardiaca cr\u00f3nica: el programa CHARM (Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0c46)\nPfeffer MA. et al. para los comit\u00e9s e invetigadores CHARMLancet 2003; 362: 759-66\n|\n|[Manejo quir\u00fargico de la mano reumatoide: consenso y controversia entre reumat\u00f3logos y cirujanos de mano (Surgical Management of the Rheumatoid Hand: Consensus and Controversy Among Rheumatologists and Hand Surgeons) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista561e)\nAlderman AK et al.Journal of Rheumatology, 2003; 30: 1464-1472\n|\n|[La terapia antirretrovial intermitente versus la continuad en el tratamiento de la infecci\u00f3n cr\u00f3nica con VIH: efectos de toxicidad del medicamento en los par\u00e1metros virol\u00f3gicos e inmunologicos. (Long-Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic Parameters ) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3b9b)\nDybul M. et alJournal of Infectious Diseases;2003:188:388-396.\n|\n|[Tratamiento interrumpido estructurado en pacientes infectados con VIH multidrogoresistente. (Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa15a)\nLawrence J et al.New England Journal of Medicine, 2003; 349:837-846\n|\n|[Anti-inflamatorios no esteroideos y riesgo de enfermedad de Parkinson (Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac1e4)\nChen H et al.Arch Neurol. 2003;60:1059-1064\n|\n|[Reducci\u00f3n en el uso de antibi\u00f3ticos entre los ni\u00f1os estadounidenses, 1996-2000 (Reduction in Antibiotic Use Among US Children, 1996\u20132000) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae28a)\nFinkelstein JA et al.Pediatrics 2003; 112:620-627.\n|\n|[Cumplimiento del tratamiento farmacol\u00f3gico y control de la presi\u00f3n arterial en pacientes del programa de hipertensi\u00f3n: Hospital V\u00edctor Lazarte Echegaray-EsSALUD, Trujillo (Per\u00fa) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8a71)\nArana Morales G, Cilliani Aguirre B, Abanto D.Revista M\u00e9dica Herediana, 2001; 12(4): 120-126\nDisponible en:\n[ www.upch.edu.pe/famed/rmh/rmh12-4/rmh12-4.pdf](http://www.upch.edu.pe/famed/rmh/rmh%2012-4/rmh12-4.pdf)\n|\n|[Automedicaci\u00f3n en cinco provincias de Cajamarca (Per\u00fa) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5116)\nLlanos F et al.Revista M\u00e9dica Herediana, 2001; 12(4): 127-133\nDisponible en:\n[ www.upch.edu.pe/famed/rmh/rmh12-4/rmh12-4.pdf](http://www.upch.edu.pe/famed/rmh/rmh%2012-4/rmh12-4.pdf)\n|\n|[Caracter\u00edsticas de la prescripci\u00f3n antibi\u00f3tica en los consultorios de medicina del hospital Cayetano Heredia de Lima, Per\u00fa ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2675)\nLlanos-Zavalaga F, Mayca P\u00e9rez J, Contreras R\u00edos CRevista Espa\u00f1ola de Salud P\u00fablica 2002; 76: 207-214\n|\n|[25 a\u00f1os de la lista de medicamentos esenciales de la OMS: avances y retos (25 years of the WHO essential medicines lists: progress and challenges) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista987f)\nLaing R et al.Lancet 2003; 361: 1723-1729\n|\n|[Las enfermeras y los farmac\u00e9uticos est\u00e1n de acuerdo: hay que cambiar (Nursing and pharmacy agree: it is time for change ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa7cf)\nThompson KKAmerican Journal of Health Systems Pharmacy 2003; 60(10): 993\n[ http://www.medscape.com/viewarticle/455694](http://www.medscape.com/viewarticle/455694)\n|\n|[Como escoger el medicamento que se va a recetar. (Choosing which drug to prescribe) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4e0d)\nKramer TAMMedescape General Medicine 2003; 5(3)\n[ http://www.medscape.com/viewarticle/459223](http://www.medscape.com/viewarticle/459223)\n|\n|[Las diferencias que hay en el mundo en el acceso a medicamentos (The global drug gap) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae86d)\nReich MRScience, 2000; 287: 1979-1981\n|\n|[Los medicamentos en las noticias: un an\u00e1lisis de la cobertura que dan los peri\u00f3dicos canadienses a los medicamentos nuevos (Drugs in the news: an an\u00e1lisis of Canadian newspaper coverage of new prescription drugs) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac904)\nCassels A, Hughes MA, Cole C, Mintzes B, Lexchin J, McCormack JPCanadian Medical Association Journal 2003; 168(9): 1133-1137\n|\n|[Ensayos cl\u00ednicos pragm\u00e1ticos: una opci\u00f3n en la construcci\u00f3n de evidencia relacionada con la salud (Pragmatic clinical trials: an option in the construction of health-related evidence ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0710)\nEvandro da Silva Freire C et al.Cad. Sa\u00fade P\u00fablica 2003; 19(4):1189-1193\n|\n|[Adherencia al tratamiento de la esquizofrenia: estudio cl\u00ednico aleatorio (Compliance therapy: a randomised controlled trial in schizophrenia) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5b08)\nO\u2019Donnell C et al.BMJ 2003;327:834\n|\n|[Profilaxis para el tromboembolismo venoso durante el tratamiento de c\u00e1ncer: una encuesta (Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9821)\nKirwan CC et al.BMJ 2003; 327:597-598\n|\n|[Un estudio cualitativo de actitudes acerca del uso de los medicamentos entre personas que sufren varias enfermedades cr\u00f3nicas (Managing multiple morbidity in mid-life: a qualitative study of attitudes to drug use) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1a44)\nTownsend A et alBMJ 2003;327:837\n|\n|[Vacuna anti-meningoc\u00f3cica para \u00c1frica: un modelo para el desarrollo de vacunas para los pa\u00edses m\u00e1s pobres (Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista28e3)\nJ\u00f3dar L, et al.Lancet 2003; 361 (9367)\n|\n|[El efecto anticompetitivo de los pseudo-gen\u00e9ricos controlados por los productores de marca en el mercado canadiense (The anti-competitive effects of brand-controlled \u201cpseudo-generics\u201d in the Canadian pharmaceutical market ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaaade)\nHollis ACanadian Public Policy- Analyse de Politiques 2003: 29: 21-32\n|\n|[Adhesi\u00f3n a las gu\u00edas de tratamiento cl\u00ednico de pacientes con diabetes tipo II en las \u00e1reas rurales: omisiones y oportunidades para mejorar (Compliance with clinical practice guidelines for type 2 diabetes in rural patients: treatment gaps and opportunities for improvement) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabd02)\nToth EL, Majumdar SR, Guirguis LM, Lewanczuk RZ, Kee TK, Johnson JAPharmacotherapy 2003; 23(5): 659-665\n|\n|[Uso de antibi\u00f3ticos en infecciones de v\u00edas respiratorias altas de ni\u00f1os atendidos en consulta externa privada ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa4aa)\nPel\u00e1ez-Ballestas I et al.Salud P\u00fablica Mex 2003; 45:159-164\n|\n|[El impacto de separar el proceso de recetar del de dispensar el medicamento en el comportamiento del proveedor de servicios: La experiencia de Taiwan (Impact of separating drug prescribing and dispensing on provider behavior: Taiwan\u2019s experience ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf632)\nChou YJ et al.Health Policy and Planning 2003; 18(3): 316-32\n|\n|[Mejorando la atenci\u00f3n primaria en el \u00e1rea rural de Alabama a trav\u00e9s de la farmacia (Improving primary care in rural Alabama with a pharmacy initiative) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae6f2)\nTaylor CT, Byrd DC, Krueger KAmerican Journal of Health System Pharmacy 2003; 60(11): 1123-1129\n|\n|[\u00bfQu\u00e9 dicen los libros de texto de farmacia sobre el tratamiento al final de la vida? (Content on end-of-life care in major pharmacy textbooks) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7bf6)\nBookwalter TC, Rabow MW, Mcphee SJAm J Health-Syst Pharm 2003; 60 (12): 1246-1250\n|\n|[Necesidades no resueltas en el proceso de utilizaci\u00f3n de medicamentos: la percepci\u00f3n de los m\u00e9dicos, farmac\u00e9uticos y de los pacientes (Unmet need in the medication use process: perceptions of physicians, pharmacists, and patients) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista613b)\nLaw AV, Ray MD, Knapp KK, Balesh JKJ Am Pharm Assoc 2003; 43(3): 394-402\n|\n|[Un programa para pasar pacientes en tratamiento con medicamentos de marca al gen\u00e9rico clozapina (A program to convert patients from trade-name to generis clozapine) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf226)\nStoner SC et al.Pharmacotherapy 2003; 23(6): 806-810\n|\n|[Estudio de errores en la medicaci\u00f3n por alergia en un hospital universitario (Assessment of medication errors that involved drug allergies at a University Hospital) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista16b4)\nAaron Jones T et al.Pharmacotherapy 2003; 23(7)\n|\n|[Revisi\u00f3n retrospectiva de utilizaci\u00f3n de medicamentos, errores de prescripci\u00f3n y consecuencias cl\u00ednicas (Retrospective Drug Utilization Review, Prescribing Errors, and Clinical Outcomes) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa7c6)\nHennessy S et alJAMA 2003; 290:1494-1499\n|\n|[Factores que influyen en la decisi\u00f3n de empezar un tratamiento preventivo: un estudio cualitativo de las actitudes de cl\u00ednicos y de personas sin entrenamiento cl\u00ednico (Factors involved in deciding to start preventive treatment: qualitative study of clinicians\u2019 and lay people\u2019s attitudes) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8ac4)\nLewis DK et al.BMJ 2003;327:841\n|\n|[Cambios en el uso de la terapia hormonorestitutiva despu\u00e9s del reporte sobre la Iniciativa de Salud de las Mujeres (Changes in use of hormone replacement therapy after the report from the Women\u2019s Health Initiative: cross sectional survey of users) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9452)\nLawton B et al.BMJ 2003; 327:845-846\n|\n|[Validez de comparaciones indirectas par estimar la eficacia de intervenciones alternativas: evicencia de meta-an\u00e1lisis publicados (Validity of indirect comparison for estimating efficacy of competing interventions: evidence from published meta-analyses) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista817a)\nSong F. et al.BMJ 2003; 326: 472-476\n|\n|[Comercializaci\u00f3n, prescripci\u00f3n y dispensaci\u00f3n de medicamentos con nombres gen\u00e9ricos en Cuba: un enfoque regulador ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2d20)\nS\u00e1nchez Gonz\u00e1lez CARev Cubana Farm 2003; 37(2)\n|\n|[Los medicamentos preventivos, \u00bfson lo suficiente preventivos? Un estudio de las expectivas que tienen los pacientes de los beneficios de los medicamentos preventivos (Are preventative drugs preventive enough? A study of patients\u00b4 expectation of benefits from preventive drugs) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6d84)\nTrewby PN. et al.Clinical Medicine 2002; 2:527-533\n|\n|[Que tan importante son las b\u00fasquedas inclusivas y las evaluaciones de calidad de ensayoe en las revisiones sistem\u00e1ticas (How important are comprehensive literature searches and the assessment of trial quality in systematic reviews. Empirical study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista642d)\nEgger M. et al.Health Technology Assessment 2003; 7:1\n|\n|[Normas farmacol\u00f3gicas cubanas: desarrollo e impacto ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabc04)\nS\u00e1nchez Gonz\u00e1lez CA y Orta Hern\u00e1ndez SDRev Cubana Farm 2003;37(2)\n[http://bvs.sld.cu/revistas/far/vol37_2_03/far06203.htm](http://bvs.sld.cu/revistas/far/vol37_2_03/far06203.htm)\n|\n|[Qu\u00e9 tan \u00fatiles son los datos no publicados de la FDA en meta-an\u00e1lisis? (How useful are unpublished data from the Food and Drug Administration in meta-analysis?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista143e)\nMacLean CH et al.Journal of Clinical Epidemiology 2003; 56: 44-51\n|\n|[Tendencias en relaci\u00f3n con la farmacovigilancia y la farmacoepidemiolog\u00eda. Un sondeo de opini\u00f3n entre docentes de farmacolog\u00eda de facultades de medicina colombianas. ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac06f)\nSegura O, Pacific HActa Med Colomb 2003; 28:112-116\n[http://www.actamedica.com/pdf/a60740310.pdf](http://www.actamedica.com/pdf/a60740310.pdf) [\n](http://www.actamedica.com/pdf/a60740310.pdf)\n|\n|[Iatrogenia en el Hospital del Ni\u00f1o \u201cDr. Ovidio Aliaga Ur\u00eda\u201d ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista128d)\nPab\u00f3n Uego CArch.argent.pediatr 2003; 101(2) y Rev. Soc. Bol. Ped. 2001;40(3):67-69\n[http://www.sap.org.ar/archivos/2003/arch03_2/conosur.pdf](http://www.sap.org.ar/archivos/2003/arch03_2/conosur.pdf)\n|\n|[Prevalencia, factores asociados y mal uso de medicamentos en los ancianos: una revisi\u00f3n. (Prevalence, associated factors, and misuse of medication in the elderly: a review) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab012)\nRozenfeld SCad. Sa\u00fade P\u00fablic 2003; 19(3):717-724\n|\n|[Estado de salud, funci\u00f3n f\u00edsica, utilizaci\u00f3n de servicios de salud y gasto en medicamentos de los ancianos brasile\u00f1os: un estudio descriptivo utilizando datos de la Encuesta Nacional de Hogares (Health status, physical functioning, health services utilization, and expenditures on medicines among Brazilian elderly: a descriptive study using data from the National Household Survey) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae1dd)\nLima-Costa, MF. et al.Cad. Sa\u00fade P\u00fablic 2003; 19(3):735-743\n|\n|[Vacunaci\u00f3n contra la hepatitis B entre odont\u00f3logos cirujanos. (Vacina\u00e7\u00e3o contra a hepatite B entre cirurgi\u00f5es dentistas.) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad988)\nBarros Lima Martins ME, Barreto SMRev. Sa\u00fade P\u00fablica 2003; 37(3)\n|\n|[Coordinaci\u00f3n de estudios multic\u00e9ntricos internacionales: estructura administrativa y reglamentaci\u00f3n. ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista456c)\nBangdiwala SI et al.Salud P\u00fablica Mex 2003; 45:58-66\n|\n|[Transferencia de los riesgos econ\u00f3micos de conceder prestaciones por productos farmac\u00e9uticos de una gran empresa proveedora de asistencia sanitaria a un consorcio de compa\u00f1\u00edas farmac\u00e9uticas (Transferring the financial risks of pharmaceutical benefits from a large health care provider in Argentina to a consortium of pharmaceutical companies) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec5d)\nCervellino JC et al.Rev Panam Salud P\u00fablica 2003; 13(4):203-213\n|\n|[Los medicamentos como factor de riesgo de ca\u00eddas en mujeres mayores de Brasil. ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7d15)\nRozenfeld S et al.Rev Panam Salud P\u00fablica 2003; 13(6):369-375\n|\n|[Consumo de medicamentos y equidad en materia de salud en el \u00c1rea Metropolitana de Buenos Aires, Argentina. ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista127e)\nAlonso VRev Panam Salud P\u00fablica 2003; 13(6):400-406\n|\n|[Normas para la publicaci\u00f3n de investigaciones cl\u00ednicas patrocinadas por la industria farmac\u00e9utica (Publication standards for clinical research sponsored by the pharmaceutical industry) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaabec)\nSin autorRev Panam Salud P\u00fablica 2003; 14(1):62-66\n|\n|[Naturaleza de los eventos adversos prevenibles en hospitales: Una revisi\u00f3n de la literatura (Nature of Preventable Adverse Drug Events in Hospitals: A Literature Review) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista39dd)\nKanjanarat P. et al.Am J Health-Syst Pharm 2003; 60(14):1750-1759\n|\n|[Encuesta descriptiva de los ensayos cl\u00ednicos financiados por entes no comerciales en el Reino Unido entre 1980-2002. (Descriptive survey of non-commercial randomised controlled trials in the United Kingdom, 1980-2002.) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab23b)\nChalmers I et al.BMJ 2003; 327: 1017\n|\n|[Comparaci\u00f3n de dos modelos de indicadores de la calidad de la prescripci\u00f3n farmac\u00e9utica en atenci\u00f3n primaria ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad657)\nG\u00f3mez-Castro MJ, Arcos P, Rubiera G, Rigueira AIGac Sanit 2003;17(5):375-83\n|\n|[Evaluaci\u00f3n econ\u00f3mica del empleo de terapias farmacol\u00f3gicas para la cesaci\u00f3n en el h\u00e1bito tab\u00e1quico ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae2b4)\nAnto\u00f1anzas F, Portillo AGac Sanit 2003;17(5):393-403\n|\n|[Prescripci\u00f3n, dispensaci\u00f3n y sustituci\u00f3n de recetas de omeprazol ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8970)\nVaquero MBGac Sanit 2003;17(4):296-301\n|\n|[Gen\u00e9ricos: \u00bfbuenos o malos? Conocimientos y actitudes de los m\u00e9dicos ante los medicamentos gen\u00e9ricos ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad12f)\nGarc\u00eda AJ, Martos F, Leiva F, S\u00e1nchez de la Cuesta FGac Sanit 2003;17(2):144-9\n|\n|[Meta an\u00e1lisis: Inhibidores de la enzima convertidora de la angiotensina y nefropat\u00eda por diabetes tipo II (angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: A meta-analysis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafb9e)\nHamilton RA, Kane MP, Demers JPharmacotherapy 2003: 23(7): 909-915\n|\n|[Asociaci\u00f3n entre la prescripci\u00f3n de antidepresivos y el suicidio en Australia: 1991-2000: estudio de tendencias (Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista66fb)\nHall WD et al.British Medical Journal 2003; 326: 1008-1012\n|\n|[Riesgo de suicidio en personas con trastorno bipolar durante el tratamiento con litio y divalproex (Suicide Risk in Bipolar Disorder During Treatment With Lithium and Divalproex) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista788f)\nGoodwin FK et alJAMA. 2003; 290:1467-1473\n|\n|[Consenso en definici\u00f3n, diagn\u00f3stico y tratamiento del insomnio (Consensus on drug treatment, definition and diagnosis for insomnia) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0d65)\nEstivill E et al.Clinical Drug Investigation 2003; 23 (6): 351-385\n|\n|[Seguridad de la terapia antidepresiva en pacientes con enfermedad cardiovascular: una revisi\u00f3n de la literatura (Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista93b8)\nAlvarez W et al.Pharmacotherapy 2003; 23 (6): 754-771\n|\n|[Tiazidas y riesgo de fractura de cadera (Thiazide Diuretics and the Risk for Hip Fracture) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9708)\nSchoofs MWCJ et al.Ann Intern Med. 2003; 139:476-482\n|\n|[Impacto de la intensidad de tratamiento con anticoagulantes orales en la mortalidad y gravedad de los embolismos cerebrales en pacientes con fibrilaci\u00f3n auricular (Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9cac)\nHylek EM et al.New England Journal of Medicine 2003; 349:1019-1026\n|\n|[Uso de azitromicina para la prevenci\u00f3n secundaria de los problemas cardiovasculares: El estudio WIZARD (Azithromycin for the Secondary Prevention of Coronary Heart Disease Events. The WIZARD Study: A Randomized Controlled Trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8294)\nO\u2019Connor CM et al.JAMA. 2003; 290:1459-1466\n|\n|[Metilxantinas para exacerbaciones de enfermedad pulmonar obstructiva cr\u00f3nica: meta an\u00e1lisis de ensayos cl\u00ednicos aleatorios (Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista282c)\nGraham Barr R et alBMJ 2003; 327:643\n|\n|[Tolerancia gastrointestinal y efectividad de rofecoxib y de naproxeno en el tratamiento de artrosis: un ensayo controlado aleatorio (Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis. A Randomized, Controlled Trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab3b7)\nLisse JR et alAnn Intern Med. 2003; 139:539-546\n|\n|[Impacto del estr\u00f3geno y la progesterona en el riesgo de fractura y en la densidad \u00f3sea. Estudio Cl\u00ednico aleatorio de la Iniciativa de Salud de la mujer (Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density. The Women\u2019s Health Initiative Randomized Trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista698c)\nCauley JA et al.JAMA. 2003; 290:1729-1738\n|\n|[Leucemia linfobl\u00e1stica aguda de c\u00e9lulas T en el ni\u00f1o: la experiencia del Consorcio del Instituto Dana-Farber de c\u00e1ncer y leucemia linfobl\u00e1stica. (Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista564d)\nGoldberg JM et alJournal of Clinical Oncology 2003; 21:3616-3622\n|\n|[Impacto del tratamiento intensivo de la diabetes mellitus tipo I en el desarrollo y la progresi\u00f3n de la nefropat\u00eda diab\u00e9tica: la epidemiolog\u00eda de las intervenciones en la diabetes y sus complicaciones. Estudio EDIC (Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy The Epidemiology of Diabetes Interventions and Complications (EDIC) Study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabc58)\nWriting Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research GroupJAMA 2003;290:2159-2167\n|\n|[Estudio de salud y envejecimiento en Bambu\u00ed (BHAS): factores asociados con el tratamiento de la hipertensi\u00f3n en ancianos en la comunidad (The Bambui Health and Aging Study (BHAS): factors associated with the treatment of hypertension in older adults in the community) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9b78)\nFirmo JOA. et al.Cad. Sa\u00fade P\u00fablic 2003; 19(3):817-827\n|\n|[Talidomida- nuevas perpectivas para utilizaci\u00f3n como antiiflamatorio, inmunosupres y antiangiog\u00e9nico. (Talidomida \u2013 novas perspectivas para utiliza\u00e7\u00e3o como antiinflamat\u00f3rio, imunossupressor e antiangiog\u00eanico). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista607f)\nGodoy Borges L, Fr\u00f6ehlich PERev Assoc Med Bras 2003; 49(1): 96-102\n|\n|[El uso de TRH combinado duplica el riesgo del c\u00e1ncer de mama. ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5c5a)\nBasado en: Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces, de Toine Lagro-Janssen, Walter W Rosser and Chris van Weel y en Breast cancer and hormone-replacement therapy in the Million Women Study, de Valerie Beral and Million Women Study CollaboratorsLancet 2003; 362:414-415,419-427\n|\n|[Relajantes musculares para la lumbalgia inespec\u00edfica: Una revisi\u00f3n sistem\u00e1tica en el marco de la colaboraci\u00f3n Cochrane (Muscle Relaxants for Nonspecific Low Back Pain: A Systematic Review Within the Framework of the Cochrane Collaboration) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0b07)\nVan Tulder MW. et al.Colaboraci\u00f3n Cochrane 2003; 28:1978-1992\n|\n|[Efectos de diferentes tratamientos hipotensores en la funci\u00f3n cardiovascualar: resultados de revisar ensayos cl\u00ednicos con un formato prospectivo (Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials). ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf6c6)\nBlood Pressure Lowering Treatment Trialists\u2019 CollaborationLancet 2003; 362:1527-35\n|\n|[Tasas de efectos adversos gastrointestinales graves producidas por aspirinas, acetaminof\u00e9n y Ibuprof\u00e9n en pacientes con ostoeartritis y artritis reumatoidea (Rates of Serious Gastrointestinal Events from Low Dose Use of Acetylsalicylic Acid, Acetaminophen, and Ibuprofen in Patients with Osteoarthritis and Rheumatoid Arthritis) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista82ad)\nFries JF, Bruce BJournal of Rheumatology 2003; 30:2226-2233\n|\n|[El tratamiento insuficiente del cancer de mama en mujeres ancianas empeora su pron\u00f3stico (Undertreatment Strongly Decreases Prognosis of Breast Cancer in Elderly Women) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1c01)\nBouchardy Ch. et al.Journal of Clinical Oncology 2003; 21:3580-3587\n|\n|[Nuevos antimicrobianos ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista95fa)\nMorej\u00f3n Garc\u00eda M et al.Rev Cubana Farm 2003; 37(2)\n[http://bvs.sld.cu/revistas/far/vol37_2_03/far09203.htm](http://bvs.sld.cu/revistas/far/vol37_2_03/far09203.htm)\n|\n|[La otitis media aguda (Acute otitis media) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista977f)\nScott EG, Powell KRInfect. Med 2003; 20 (5): 224-229\n|\n|[Eficacia cl\u00ednica y bacteriol\u00f3gica de dosis altas de amoxicilina para el tratamiento de la otitis media aguda en ni\u00f1os (Bacteriologic and clinical efficacy of high dose amoxicilin for therapy of acute otitis media in children) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae37a)\nPiglanski L, Leibovitz E, Raiz S, Greenberg D, Press J, Leiberman A, Dagan RPediatric Infectious Diseases Journal 2003; 22 (5): 405-413\n|\n|[La adhesi\u00f3n al tratamiento no es una barrera para el \u00e9xito de la terapia antirretroviral en Sud\u00e1frica (adhrence is not a barrier to succesful antiretrovial therapy in South Africa) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7c66)\nOrrell C et al.AIDS 2003; 17 (9): 1369-1376\n|\n|[Puesta al d\u00eda de los errores en la prescripci\u00f3n de HAART (Update on prescribing errors with HAART) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista96a5)\nFaragon JJ et al.AIDS Read 2003; 13 (6): 268-278\n|\n|[Substituci\u00f3n de inhibidores de proteasa por neviparina, efavirenz o abacavir en pacientes con VIH (Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad4d2)\nMart\u00ednez E et al.New England Journal of Medicine 2003; 349:1036-1046\n|\n|[Profilaxis postexposici\u00f3n corta en los reci\u00e9n nacidos para reducir la trasmisi\u00f3n de madre a infante del VIH-1: un ensayo cl\u00ednico aleatorio de NVAZ (Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0c9a)\nNewton TE et al.Lancet 2003; 362: 1171-77\n|\n|[Efecto de la administraci\u00f3n de dosis \u00fanica de neviparina durante el parto y el per\u00edodo neonatal comparado con el tratamiento con zidovudina en la prevenci\u00f3n de la transmisi\u00f3n de HIV-1 de madre a hijo en Kampala, Uganda. Estudio cl\u00ednico aleatorio HIVNET, 18 meses de seguimiento (Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafc90)\nJackson JB et alLancet 2003; 362:859-68\n|\n|[Terapia antirretroviral combinada y riesgo de infarto de miocardio (Combination Antiretroviral Therapy and the Risk of Myocardial Infarction) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2a8e)\nGrupo del estudio DAD (Data Collection on Adverse Events of Anti-HIV Drugs)N Engl J Med 2003; 349:1993-2003\n|\n|[Relaci\u00f3n entre uso previo de antimicrobiales, resistencia antimicrobial y resultado del tratamiento para infecciones de H. pylory (The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista31a1)\nMcMahon B et al.Ann Intern Med. 2003; 139:463-469\n|\n|[Se requiere dosis de recuerdo para estar inmunizado contra la hepatitis A? ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab902)\nThe International Consensus Group on Hepatitis A Virus Immunity Van Damme P et al.Lancet 2003; 362: 1065-71\n|\n|[Eficacia terap\u00e9utica de tres esquemas de tratamiento de malaria no complicada por Plasmodium falciparum, Antioquia, Colombia, 2002 ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae3f0)\nBlair S et al.Biom\u00e9dica 2003; 23:318-27\n[http://www.ins.gov.co/publicaciones/2003_biomedica_233.pdf](http://www.ins.gov.co/publicaciones/2003_biomedica_233.pdf)\n|\n|[Resistencia a antimicrobianos y evaluaci\u00f3n del tratamiento combinado en la septicemia neonatal ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista36d6)\nEspino Hern\u00e1ndez M et al.Rev Panam Salud P\u00fablica 2003; 13(4):214-221\n|\n|[Tolerabilidad de la quimiprofilaxis para prevenir la malaria entre persones no inmunes que viajan al \u00c1frica: estudio multic\u00e9ntrico, aleatorizado, de dobre ciego y 4 grupos Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7f4e)\nSchlagenhauf P et al.BMJ 2003; 327:1078\n|\n|[Ensayo cl\u00ednico que compara el efecto de 8 versus 15 d\u00edas de tratamiento antibioticoter\u00e1pico en pacientes con neumon\u00eda asociada al uso de un respirador artificial (Comparison of 8 vs 15 Days of Antibiotic Therapy for Ventilator-Associated Pneumonia in Adults. A Randomized Trial) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3402)\nChastre J. et alJAMA. 2003;290:2588-2598\n|\n|[Relaci\u00f3n entre el uso previo de antibi\u00f3ticos, la resistencia antimicrobiana y el resultado del tratamiento de la infecci\u00f3n por H. pylori (The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf5d8)\nMcMahon B et al.Ann Intern Med. 2003; 139:463-469\n|\n|[Qu\u00e9 se les debe aconsejar a los pacientes sobre el consumo de antioxidantes? (What should we advise our patients about taking antioxidants?) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae12d)\nPickering TGJ Clin Hypertens 2003; 5(3): 231-233\n|\n|[Revisi\u00f3n de los resultados anormales en las pruebas de laboratorio y toxicidad por el uso de plantas medicinales (Review of abnormal laboratory test results and toxic effects due to use of herbal medicine) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8d8b)\nDasgupta AAm J Clin Pathol 2003: 120 (1): 127-137\n|\n|[Comercializaci\u00f3n por internet de productos extra\u00eddos de plantas medicinales (Internet Marketing of Herbal Products) ](https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista00d7)\nMorris CA et al.JAMA. 2003; 290:1505-1509", "language": null, "image": null, "pagetype": null, "links": ["https://www.saludyfarmacos.org", "#", "https://www.saludyfarmacos.org/salud-y-farmacos/quienes-somos/", "https://www.saludyfarmacos.org/salud-y-farmacos/junta-directiva/", "https://www.saludyfarmacos.org/salud-y-farmacos/consejo-asesor/", "https://www.saludyfarmacos.org/salud-y-farmacos/nuestro-logo/", "#", "https://www.saludyfarmacos.org/actividades/relaciones-con-otras-instituciones/", "https://www.saludyfarmacos.org/actividades/investigation/", "https://www.saludyfarmacos.org/publicaciones/presentaciones/", "https://www.saludyfarmacos.org/publicaciones/", "https://www.saludyfarmacos.org/publicaciones/informes/", "https://www.saludyfarmacos.org/publicaciones/articles/", "#", "https://www.saludyfarmacos.org/last-newsletters/", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/", "https://www.saludyfarmacos.org/boletin-farmacos/boletines-portugues/", "https://www.saludyfarmacos.org/subscribirse/", "https://www.saludyfarmacos.org/boletin-farmacos/historia/", "https://www.saludyfarmacos.org/boletin-farmacos/contenido/", "https://www.saludyfarmacos.org/boletin-farmacos/equipo-editorial/", "https://www.saludyfarmacos.org/boletin-farmacos/conflicto-intereses/", "https://www.saludyfarmacos.org/boletin-farmacos/informacion-para-los-autores-de-articulos-2/", "https://www.saludyfarmacos.org/categorias/noticias-principales/", "https://www.saludyfarmacos.org/relem/", "https://www.saludyfarmacos.org/financiacion/", "https://www.saludyfarmacos.org/videos/", "#", "https://www.saludyfarmacos.org/servicios/", "https://www.saludyfarmacos.org/como-ayudar/", "https://www.saludyfarmacos.org/donation/", "https://www.saludyfarmacos.org/lang/es/boletin-farmacos/boletines/jun2001/indice", "https://www.saludyfarmacos.org/lang/en/boletin-farmacos/boletines/jun2001/indice", "https://www.saludyfarmacos.org/boletin-farmacos/boletines-portugues/", "#", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/ventana-abierta", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/comunicaciones", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/noticias", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/investigaciones", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/medicamentos-cuestionados", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/practicas-recomendables", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/etica-y-medicamentos", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/titulos-recientes", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/recursos-electronicos", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/revista-de-revistas", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indices", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/autores-de-articulos", "https://www.saludyfarmacos.org", "#", null, "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/ventana-abierta", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/comunicaciones", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/noticias", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/investigaciones", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/medicamentos-cuestionados", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/practicas-recomendables", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/etica-y-medicamentos", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/titulos-recientes", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/recursos-electronicos", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/revista-de-revistas", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9b08", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista30f6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5895", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista78ef", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista78ef", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista78ef", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista78ef", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista78ef", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista78ef", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista78ef", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1462", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1462", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1462", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1462", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1462", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1462", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab93b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab93b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab93b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab93b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab93b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab93b", "mailto:phon1993@hotmail.com", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9589", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9589", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9589", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9589", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9589", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5ead", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5ead", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5ead", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5ead", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5ead", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec8e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec8e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec8e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec8e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec8e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab540", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab540", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab540", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab540", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab540", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista90bd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista90bd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista90bd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista90bd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista90bd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0066", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0066", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0066", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0066", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0066", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5b94", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5b94", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5b94", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5b94", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5b94", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4e7a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4e7a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4e7a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4e7a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4e7a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaca86", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaca86", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaca86", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaca86", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaca86", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf5d9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf5d9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf5d9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf5d9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf5d9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1bbb", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1bbb", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1bbb", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1bbb", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1bbb", "http://www.medscape.com/Medscape/pharmacists/journal/2001/v02.n02", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4cad", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7818", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7818", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7818", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7818", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista855c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista855c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista855c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista855c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2b12", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2b12", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2b12", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2b12", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3b55", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3b55", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3b55", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3b55", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista34f5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista34f5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista34f5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista34f5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac590", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac590", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac590", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac590", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaddd8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaddd8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaddd8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaddd8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac38d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac38d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac38d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac38d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf0fe", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf0fe", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf0fe", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf0fe", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista97c1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista97c1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista97c1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista97c1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista08b9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista08b9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista08b9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2f26", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2f26", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2f26", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0e46", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0e46", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0e46", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae356", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae356", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae356", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf218", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf218", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9911", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9911", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf940", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf940", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabfee", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabfee", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistacea3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistacea3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab3ea", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab3ea", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8a1d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8a1d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista670c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista670c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista88bd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista88bd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista453d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista453d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf3d1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf3d1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista54e6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista54e6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0ac6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0ac6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5d6c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5d6c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista64b8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista64b8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista59bb", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista59bb", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf563", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf563", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae9a4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae9a4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistade22", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistade22", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2acd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2acd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf271", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf271", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6449", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6449", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista037e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista037e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaaff0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaaff0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0e91", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0e91", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista09be", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista09be", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistadb36", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistadb36", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5a20", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5a20", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3888", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1e0e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac25c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaabfd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf490", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9033", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae1e6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8584", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista72f3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista72e9", "mailto:jwatal@iie.com", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3dae", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6214", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1cf0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1945", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae66c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab90c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafacf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac866", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista55e4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1c2a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa224", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista27f6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista254b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5e4e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa084", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista54b9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista175f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista964a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8675", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1e0e-2", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2861", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae9bf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6969", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2fc9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistacb36", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac4a6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9e6d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae76e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3fb3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7400", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaedbf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista877b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista938f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1473", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2ee5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0902", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafbfe", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista54f9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec3a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0625", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf3f3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0ac0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8678", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista851a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaea81", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2b02", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista77e9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3c7c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista629c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec61", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista86ae", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7f43", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8e77", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1e3e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab4aa", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista23c9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8788", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7737", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab999", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1304", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista73a0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0a47", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9eda", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8a8f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad853", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista233e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista37d0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9257", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf10e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista89a4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa24b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1557", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa73f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafeb1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac272", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista488a", "http://www.cdc.gov/mmwr", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad186", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7ae6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3b59", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista963d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5839", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae241", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8c15", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7492", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaac5f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2fa1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3877", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae465", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafba0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf0b9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1b1c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6120", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafe13", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista91d8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista72c2", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7728", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista22b5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista60cd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistadfad", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8839", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaca1e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3e4e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf97f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4239", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista61d1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae255", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista369c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2651", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista51cf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae8b6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac888", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab3f8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista098f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae80c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad73c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3011", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabe85", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaef80", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5a4e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab7b2", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8ab7", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3aa1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3306", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0c52", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5e67", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista23e6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2169", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad7f2", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1627", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae493", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae40d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6598", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista84d7", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4e85", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3c8a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista55f3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3528", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabbb5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa4c3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7ab9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4a1b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabda0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista54cc", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaae2a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9535", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5324", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista17f9", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1e26", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac4ef", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista12e1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7faa", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae44b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae7bd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae813", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3a74", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac339", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaef71", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf1a7", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac072", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista767c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2475", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista73a7", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1e4d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabfe0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista16e1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8aa3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista680b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae504", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa3c7", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0272", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaad34", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9767", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4d4f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista029e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9890", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa800", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa7d4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad89c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista316d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2c1e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista315a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaebc7", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa25e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista48fb", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0a61", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa36b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9647", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9937", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaee7d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4489", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista103d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7f8d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaaecf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista843b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8e6a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista95c4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3d83", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae6e6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabeb0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac9b6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaabea", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab6a2", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae847", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4d9b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec63", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad04e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3d4e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3104", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1a97", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista79f0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8fa5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista83d4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad06e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista74d4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7a13", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa543", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1ea4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9094", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1fc5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistacffd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista049c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista17a6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae9b3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8b6f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6668", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista71c4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6a4b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5479", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista50dc", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad39c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7e92", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2a78", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista71fe", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7b9d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad037", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7f62", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista80c5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista659b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafcf0", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistada17", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3843", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista86c7", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6ac5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista41c7", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8d96", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista607b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2731", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2924", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab6dd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab21c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6943", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5ca3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistada40", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaeaa2", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistacb0f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabc09", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabc23", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3fed", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista865a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3091", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista24c3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9583", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaeea6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac3ab", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad88d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabe83", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafbdf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistadb07", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6db1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9473", "http://www.thelancet.com/journal/vol361/iss9351/full/llan.361.9351.original%20_research.23828.1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista217a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaeb5a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista17c2", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1cea", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac61e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2fec", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac5c8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae470", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0b66", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6218", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista417d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabab3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2b09", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabe47", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac36b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistacbc4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6faa", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistadf6c", "http://www.thelancet.com/journal/vol361/iss9366/full/llan.361.9366.original_research.25317.1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaee94", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista833c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista08a4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae8d4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabfc9", "http://content.nejm.org/cgi/content/short/348/16/1556", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9104", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac1f2", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8bc3", "http://www.cmaj.ca/cgi/content/abstract/168/9/1133", "http://www.policyalternatives.ca/", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2d4a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7ad8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistadc2f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa102", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf7cb", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4e07", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4352", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae81c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaedaf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabb1b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaeb98", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac467", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaed2b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista318c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafe82", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5b93", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3b0a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabddd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad258", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6be6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8b0a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1d23", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista661f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8de6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7e0d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista049c-2", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae888", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1d83", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaea4a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4b61", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0c46", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista561e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3b9b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa15a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac1e4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae28a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8a71", "http://www.upch.edu.pe/famed/rmh/rmh%2012-4/rmh12-4.pdf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5116", "http://www.upch.edu.pe/famed/rmh/rmh%2012-4/rmh12-4.pdf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2675", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista987f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa7cf", "http://www.medscape.com/viewarticle/455694", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista4e0d", "http://www.medscape.com/viewarticle/459223", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae86d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac904", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0710", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5b08", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9821", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1a44", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista28e3", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaaade", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabd02", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa4aa", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf632", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae6f2", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7bf6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista613b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf226", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista16b4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaa7c6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8ac4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9452", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista817a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2d20", "http://bvs.sld.cu/revistas/far/vol37_2_03/far07203.htm", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista6d84", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista642d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabc04", "http://bvs.sld.cu/revistas/far/vol37_2_03/far06203.htm", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista143e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistac06f", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "http://www.actamedica.com/pdf/a60740310.pdf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista128d", "http://www.sap.org.ar/archivos/2003/arch03_2/conosur.pdf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab012", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae1dd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad988", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista456c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaec5d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7d15", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista127e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaabec", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista39dd", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab23b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad657", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae2b4", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8970", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad12f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafb9e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista66fb", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista788f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0d65", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista93b8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9708", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9cac", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8294", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista282c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab3b7", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista698c", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista564d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistabc58", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista9b78", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista607f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista5c5a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0b07", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf6c6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista82ad", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista1c01", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista95fa", "http://bvs.sld.cu/revistas/far/vol37_2_03/far09203.htm", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista977f", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae37a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7c66", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista96a5", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistad4d2", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista0c9a", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistafc90", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista2a8e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista31a1", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistab902", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae3f0", "http://www.ins.gov.co/publicaciones/2003_biomedica_233.pdf", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista36d6", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista7f4e", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista3402", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistaf5d8", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revistae12d", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista8d8b", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indice-revista00d7", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/indices", "https://www.saludyfarmacos.org/boletin-farmacos/boletines/jun2001/autores-de-articulos", "https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es", "https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es", "https://twitter.com/SaludyFarmacos", "https://www.facebook.com/SaludyFarmacos/", "https://www.linkedin.com/company/saludyfarmacos"]}